JP4173191B2 - H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 - Google Patents
H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 Download PDFInfo
- Publication number
- JP4173191B2 JP4173191B2 JP2007512541A JP2007512541A JP4173191B2 JP 4173191 B2 JP4173191 B2 JP 4173191B2 JP 2007512541 A JP2007512541 A JP 2007512541A JP 2007512541 A JP2007512541 A JP 2007512541A JP 4173191 B2 JP4173191 B2 JP 4173191B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- pyran
- tetrahydro
- pyrrolidin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 4-monosubstituted phenol Chemical class 0.000 title claims description 174
- 239000003446 ligand Substances 0.000 title description 13
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 382
- 238000000034 method Methods 0.000 claims description 102
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 89
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000005843 halogen group Chemical group 0.000 claims description 39
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 38
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 16
- 125000003282 alkyl amino group Chemical group 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- YSYGZKGNABJODU-UHFFFAOYSA-N n-methyl-1-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNC)CCOCC1 YSYGZKGNABJODU-UHFFFAOYSA-N 0.000 claims description 12
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 206010028735 Nasal congestion Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 150000003254 radicals Chemical class 0.000 claims description 7
- 239000011593 sulfur Chemical group 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 208000002173 dizziness Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- AMBOFCGRXVMRID-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(3-thiomorpholin-4-ylpropoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCSCC2)C=CC=1C1(CN(C)C)CCOCC1 AMBOFCGRXVMRID-UHFFFAOYSA-N 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 4
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 4
- 206010064948 Viral rhinitis Diseases 0.000 claims description 4
- 230000008369 airway response Effects 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- WGDFTJNWMYTBQE-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(4-pyrrolidin-1-ylbutoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCCN2CCCC2)C=CC=1C1(CN(C)C)CCOCC1 WGDFTJNWMYTBQE-UHFFFAOYSA-N 0.000 claims description 4
- HNZKTOBSYDHYRA-UHFFFAOYSA-N n,n-dimethyl-4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxane-4-carboxamide Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C(=O)N(C)C)C=C1 HNZKTOBSYDHYRA-UHFFFAOYSA-N 0.000 claims description 4
- ZTAFYMFDNHMIDY-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]propan-2-amine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNC(C)C)CCOCC1 ZTAFYMFDNHMIDY-UHFFFAOYSA-N 0.000 claims description 4
- XCBZZBZFEZRWTG-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]propan-2-amine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)C(C)C)CCOCC1 XCBZZBZFEZRWTG-UHFFFAOYSA-N 0.000 claims description 4
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 4
- XSRHKGWPQMRZGQ-HSZRJFAPSA-N (2r)-2-(methoxymethyl)-1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyrrolidine Chemical compound COC[C@H]1CCCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 XSRHKGWPQMRZGQ-HSZRJFAPSA-N 0.000 claims description 3
- XSRHKGWPQMRZGQ-QHCPKHFHSA-N (2s)-2-(methoxymethyl)-1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyrrolidine Chemical compound COC[C@@H]1CCCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 XSRHKGWPQMRZGQ-QHCPKHFHSA-N 0.000 claims description 3
- CDJWGNRCKYMVEG-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1CN(C)CCN1C(=O)C1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 CDJWGNRCKYMVEG-UHFFFAOYSA-N 0.000 claims description 3
- QAFCRXAXGCPIAH-UHFFFAOYSA-N (4-propylpiperazin-1-yl)-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1CN(CCC)CCN1C(=O)C1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 QAFCRXAXGCPIAH-UHFFFAOYSA-N 0.000 claims description 3
- YRFADXLNLBNIIT-UHFFFAOYSA-N 1,1,3-trimethyl-3-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]urea Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)C(=O)N(C)C)CCOCC1 YRFADXLNLBNIIT-UHFFFAOYSA-N 0.000 claims description 3
- HMWUZYVXFWDKHD-UHFFFAOYSA-N 1-[3-[4-[4-[(dimethylamino)methyl]oxan-4-yl]phenoxy]propyl]-n,n-dimethylazetidin-3-amine Chemical compound C=1C=C(OCCCN2CC(C2)N(C)C)C=CC=1C1(CN(C)C)CCOCC1 HMWUZYVXFWDKHD-UHFFFAOYSA-N 0.000 claims description 3
- ITUMHEKFUUXBAG-UHFFFAOYSA-N 1-[3-[4-[4-[(dimethylamino)methyl]oxan-4-yl]phenoxy]propyl]piperidin-4-ol Chemical compound C=1C=C(OCCCN2CCC(O)CC2)C=CC=1C1(CN(C)C)CCOCC1 ITUMHEKFUUXBAG-UHFFFAOYSA-N 0.000 claims description 3
- HPLCRROSPJXLHU-UHFFFAOYSA-N 1-[3-[4-[4-[(dimethylamino)methyl]oxan-4-yl]phenoxy]propyl]piperidine-4-carboxamide Chemical compound C=1C=C(OCCCN2CCC(CC2)C(N)=O)C=CC=1C1(CN(C)C)CCOCC1 HPLCRROSPJXLHU-UHFFFAOYSA-N 0.000 claims description 3
- PZZDRYKSGLXTQN-UHFFFAOYSA-N 1-[4-[4-[3-(1,1-dioxo-1,4-thiazinan-4-yl)propoxy]phenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C=1C=C(OCCCN2CCS(=O)(=O)CC2)C=CC=1C1(CN(C)C)CCOCC1 PZZDRYKSGLXTQN-UHFFFAOYSA-N 0.000 claims description 3
- UPHRKBXEQZNQTE-UHFFFAOYSA-N 1-[4-[4-[3-(2,5-dimethylpyrrolidin-1-yl)propoxy]phenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound CC1CCC(C)N1CCCOC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 UPHRKBXEQZNQTE-UHFFFAOYSA-N 0.000 claims description 3
- MKBBVOXGASEJQR-UHFFFAOYSA-N 1-[4-[4-[3-(4-methoxypiperidin-1-yl)propoxy]phenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C1CC(OC)CCN1CCCOC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 MKBBVOXGASEJQR-UHFFFAOYSA-N 0.000 claims description 3
- SXELEQWVJKYITC-UHFFFAOYSA-N 1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]imidazo[4,5-b]pyridine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2C3=CC=CN=C3N=C2)CCOCC1 SXELEQWVJKYITC-UHFFFAOYSA-N 0.000 claims description 3
- HERLQHABDNPAFE-UHFFFAOYSA-N 1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]imidazo[4,5-c]pyridine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2C3=CC=NC=C3N=C2)CCOCC1 HERLQHABDNPAFE-UHFFFAOYSA-N 0.000 claims description 3
- NWZGKUDNQWHIRC-UHFFFAOYSA-N 1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperidine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2CCCCC2)CCOCC1 NWZGKUDNQWHIRC-UHFFFAOYSA-N 0.000 claims description 3
- DXDLHXHFANZYEZ-UHFFFAOYSA-N 1-methyl-4-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]piperazine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CN3CCN(C)CC3)CCOCC2)C=C1 DXDLHXHFANZYEZ-UHFFFAOYSA-N 0.000 claims description 3
- NAMQZVSTQJEWDB-UHFFFAOYSA-N 1-methyl-4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine Chemical compound C1CN(C)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 NAMQZVSTQJEWDB-UHFFFAOYSA-N 0.000 claims description 3
- GWKSUDJAXWYYKI-UHFFFAOYSA-N 1-phenyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]methanesulfonamide Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)CNS(=O)(=O)CC1=CC=CC=C1 GWKSUDJAXWYYKI-UHFFFAOYSA-N 0.000 claims description 3
- SLAHXGLOXBNZRA-UHFFFAOYSA-N 1-propan-2-yl-4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine Chemical compound C1CN(C(C)C)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 SLAHXGLOXBNZRA-UHFFFAOYSA-N 0.000 claims description 3
- LSYDVIMXNCBKNG-UHFFFAOYSA-N 2-[methyl-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]amino]ethanol Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(CCO)C)CCOCC1 LSYDVIMXNCBKNG-UHFFFAOYSA-N 0.000 claims description 3
- MJNVSNSVKMQCEO-UHFFFAOYSA-N 2-fluoro-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]benzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NCC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 MJNVSNSVKMQCEO-UHFFFAOYSA-N 0.000 claims description 3
- CQDZTEFRQUXWIS-UHFFFAOYSA-N 2-methylsulfanyl-1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]imidazole Chemical compound CSC1=NC=CN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 CQDZTEFRQUXWIS-UHFFFAOYSA-N 0.000 claims description 3
- SXJMICVRCSUCAE-UHFFFAOYSA-N 3-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]imidazo[4,5-b]pyridine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2C3=NC=CC=C3N=C2)CCOCC1 SXJMICVRCSUCAE-UHFFFAOYSA-N 0.000 claims description 3
- YJRFDELTDMFEAD-UHFFFAOYSA-N 3-[[methyl-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]amino]methyl]phenol Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)CN(C)CC1=CC=CC(O)=C1 YJRFDELTDMFEAD-UHFFFAOYSA-N 0.000 claims description 3
- KRQYQEXCIAQVCL-UHFFFAOYSA-N 4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-n,n-dimethyloxane-4-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1C1(C(=O)N(C)C)CCOCC1 KRQYQEXCIAQVCL-UHFFFAOYSA-N 0.000 claims description 3
- HMPMHACJMYGXPE-UHFFFAOYSA-N 4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxane-4-carboxamide Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C(N)=O)C=C1 HMPMHACJMYGXPE-UHFFFAOYSA-N 0.000 claims description 3
- OFXQUDWAMFPAAR-UHFFFAOYSA-N 4-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]morpholine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CN3CCOCC3)CCOCC2)C=C1 OFXQUDWAMFPAAR-UHFFFAOYSA-N 0.000 claims description 3
- ASPKIWTUTQSIMZ-UHFFFAOYSA-N 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]-1,4-thiazinane 1,1-dioxide Chemical compound C1CS(=O)(=O)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 ASPKIWTUTQSIMZ-UHFFFAOYSA-N 0.000 claims description 3
- YQQHEXVQNHKNLB-UHFFFAOYSA-N 4-[[4-[4-[(1-cyclopentylazetidin-3-yl)methoxy]phenyl]oxan-4-yl]methyl]morpholine Chemical compound C1N(C2CCCC2)CC1COC(C=C1)=CC=C1C1(CN2CCOCC2)CCOCC1 YQQHEXVQNHKNLB-UHFFFAOYSA-N 0.000 claims description 3
- TXPZDHACJZHFNY-UHFFFAOYSA-N 6-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyridin-3-amine Chemical compound C1=NC(C)=CC=C1NCC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 TXPZDHACJZHFNY-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 3
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- JQBYDXDNFVDPRZ-UHFFFAOYSA-N [4-[4-(3-piperidin-1-ylpropoxy)phenyl]oxan-4-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C=1C=C(OCCCN2CCCCC2)C=CC=1C1(CN)CCOCC1 JQBYDXDNFVDPRZ-UHFFFAOYSA-N 0.000 claims description 3
- KYUVIJVAROUIJL-UHFFFAOYSA-N [4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN)CCOCC1 KYUVIJVAROUIJL-UHFFFAOYSA-N 0.000 claims description 3
- CGLHGLGESNEJBQ-UHFFFAOYSA-N [4-[4-[3-(1,4-oxazepan-4-yl)propoxy]phenyl]oxan-4-yl]-piperazin-1-ylmethanone Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCOCCC2)=CC=1)C(=O)N1CCNCC1 CGLHGLGESNEJBQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- HCGITLJZDQEJPA-UHFFFAOYSA-N azetidin-1-yl-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methanone Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C(=O)N2CCC2)C=C1 HCGITLJZDQEJPA-UHFFFAOYSA-N 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 3
- LMRFKMLIDRGNRM-UHFFFAOYSA-N ethyl 2-[3-[4-[4-[(dimethylamino)methyl]oxan-4-yl]phenoxy]propyl]piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1CCCOC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 LMRFKMLIDRGNRM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- RZHNUKIJVHIANX-UHFFFAOYSA-N n,n-dimethyl-1-[1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexyl]methanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)C)CCCCC1 RZHNUKIJVHIANX-UHFFFAOYSA-N 0.000 claims description 3
- VOOMNBIHQWHHQU-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methanamine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 VOOMNBIHQWHHQU-UHFFFAOYSA-N 0.000 claims description 3
- ZVNUDSVFEBSZEN-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCN2CCCC2)C=CC=1C1(CN(C)C)CCOCC1 ZVNUDSVFEBSZEN-UHFFFAOYSA-N 0.000 claims description 3
- JYNIFNSNENUZCW-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(3-morpholin-4-ylpropoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCOCC2)C=CC=1C1(CN(C)C)CCOCC1 JYNIFNSNENUZCW-UHFFFAOYSA-N 0.000 claims description 3
- XHTSWANPJGWLBJ-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(3-pyrrolidin-1-ylbutoxy)phenyl]oxan-4-yl]methanamine Chemical compound C1CCCN1C(C)CCOC(C=C1)=CC=C1C1(CN(C)C)CCOCC1 XHTSWANPJGWLBJ-UHFFFAOYSA-N 0.000 claims description 3
- LDQKGIXYOXNCCH-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(4-pyrrolidin-1-ylbutan-2-yloxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(C2(CN(C)C)CCOCC2)C=CC=1OC(C)CCN1CCCC1 LDQKGIXYOXNCCH-UHFFFAOYSA-N 0.000 claims description 3
- UKDSQZDQZBJEBR-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-[2-(1-methylpyrrolidin-2-yl)ethoxy]phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCC2N(CCC2)C)C=CC=1C1(CN(C)C)CCOCC1 UKDSQZDQZBJEBR-UHFFFAOYSA-N 0.000 claims description 3
- ONNIRXJINOOIMP-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-[3-(1-oxo-1,4-thiazinan-4-yl)propoxy]phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCS(=O)CC2)C=CC=1C1(CN(C)C)CCOCC1 ONNIRXJINOOIMP-UHFFFAOYSA-N 0.000 claims description 3
- AEIOQTZNNPIEDH-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]oxan-4-yl]methanamine Chemical compound CC1CCCN1CCCOC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 AEIOQTZNNPIEDH-UHFFFAOYSA-N 0.000 claims description 3
- XDMCRGNPUBBHDR-UHFFFAOYSA-N n-[[4-[4-(1-ethylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]pyridin-2-amine Chemical compound C1CN(CC)CCC1OC1=CC=C(C2(CNC=3N=CC=CC=3)CCOCC2)C=C1 XDMCRGNPUBBHDR-UHFFFAOYSA-N 0.000 claims description 3
- MQSUQXYTEPOGOW-UHFFFAOYSA-N n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]ethanamine Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C=CC=1C1(CNCC)CCOCC1 MQSUQXYTEPOGOW-UHFFFAOYSA-N 0.000 claims description 3
- DTDCZRMTIIDTMM-UHFFFAOYSA-N n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]pyridazin-4-amine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CNC=3C=NN=CC=3)CCOCC2)C=C1 DTDCZRMTIIDTMM-UHFFFAOYSA-N 0.000 claims description 3
- NDCNMFKZSHBIMR-UHFFFAOYSA-N n-[[4-[4-(3-piperidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyridin-2-amine Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1C1(CNC=2N=CC=CC=2)CCOCC1 NDCNMFKZSHBIMR-UHFFFAOYSA-N 0.000 claims description 3
- ORBQAZKYMKCIEU-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]cyclopentanamine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CNC2CCCC2)CCOCC1 ORBQAZKYMKCIEU-UHFFFAOYSA-N 0.000 claims description 3
- OZJFBFMGMMMAFS-UHFFFAOYSA-N n-[[4-[4-(4-pyrrolidin-1-ylbutoxy)phenyl]oxan-4-yl]methyl]pyridin-2-amine Chemical compound C=1C=C(C2(CNC=3N=CC=CC=3)CCOCC2)C=CC=1OCCCCN1CCCC1 OZJFBFMGMMMAFS-UHFFFAOYSA-N 0.000 claims description 3
- XDGWWNNKYYPMLX-UHFFFAOYSA-N n-methyl-1-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C=CC=1C1(CNC)CCOCC1 XDGWWNNKYYPMLX-UHFFFAOYSA-N 0.000 claims description 3
- SOQQXINUWMFHKG-UHFFFAOYSA-N n-methyl-2-phenyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)CN(C)CCC1=CC=CC=C1 SOQQXINUWMFHKG-UHFFFAOYSA-N 0.000 claims description 3
- FIFUBMMWDKBRMU-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]acetamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)C(C)=O)CCOCC1 FIFUBMMWDKBRMU-UHFFFAOYSA-N 0.000 claims description 3
- LHFZKDAWTYMZPM-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]cyclopentanamine Chemical compound C1CCCC1N(C)CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 LHFZKDAWTYMZPM-UHFFFAOYSA-N 0.000 claims description 3
- QPQBUHKKPZDZER-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]methanesulfonamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)S(C)(=O)=O)CCOCC1 QPQBUHKKPZDZER-UHFFFAOYSA-N 0.000 claims description 3
- DNICJXVQUJDBKN-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pentan-1-amine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)CCCCC)CCOCC1 DNICJXVQUJDBKN-UHFFFAOYSA-N 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 125000005961 oxazepanyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 230000035882 stress Effects 0.000 claims description 3
- YLRAIHIZJMBQNV-UHFFFAOYSA-N (4-methyl-1,4-diazepan-1-yl)-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1CN(C)CCCN1C(=O)C1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 YLRAIHIZJMBQNV-UHFFFAOYSA-N 0.000 claims description 2
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims description 2
- XOOXJGUZNPIDIB-UHFFFAOYSA-N 1-(cyclopropylmethyl)-4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2CCN(CC3CC3)CC2)CCOCC1 XOOXJGUZNPIDIB-UHFFFAOYSA-N 0.000 claims description 2
- SVYHIFULYRWEJF-UHFFFAOYSA-N 1-cyclopropyl-n-(cyclopropylmethyl)-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]methanamine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN(CC2CC2)CC2CC2)CCOCC1 SVYHIFULYRWEJF-UHFFFAOYSA-N 0.000 claims description 2
- 208000027219 Deficiency disease Diseases 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- WQJGXTQMBHTWHE-UHFFFAOYSA-N n,3,3-trimethyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]butan-1-amine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(CCC(C)(C)C)C)CCOCC1 WQJGXTQMBHTWHE-UHFFFAOYSA-N 0.000 claims description 2
- PIMXHGWKKJXNDQ-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-[3-(4-methyl-1,4-diazepan-1-yl)propoxy]phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCN(C)CCC2)C=CC=1C1(CN(C)C)CCOCC1 PIMXHGWKKJXNDQ-UHFFFAOYSA-N 0.000 claims description 2
- KQGXOAMXMMQKTQ-UHFFFAOYSA-N n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]pyridin-2-amine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CNC=3N=CC=CC=3)CCOCC2)C=C1 KQGXOAMXMMQKTQ-UHFFFAOYSA-N 0.000 claims description 2
- OOAPQINQOLWPEV-UHFFFAOYSA-N n-ethyl-n-methyl-3-[4-[4-(morpholin-4-ylmethyl)oxan-4-yl]phenoxy]propan-1-amine Chemical compound C1=CC(OCCCN(C)CC)=CC=C1C1(CN2CCOCC2)CCOCC1 OOAPQINQOLWPEV-UHFFFAOYSA-N 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- XZMSQXMEJSHESY-UHFFFAOYSA-N n-methyl-2-methylsulfonyl-n-[[4-[4-(3-morpholin-4-ylpropoxy)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound C=1C=C(OCCCN2CCOCC2)C=CC=1C1(CN(CCS(C)(=O)=O)C)CCOCC1 XZMSQXMEJSHESY-UHFFFAOYSA-N 0.000 claims 6
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 4
- VJVZRIYYTOCVSU-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-[4-[3-(1,4-oxazepan-4-yl)propoxy]phenyl]oxan-4-yl]methanone Chemical compound C1CN(C)CCN1C(=O)C1(C=2C=CC(OCCCN3CCOCCC3)=CC=2)CCOCC1 VJVZRIYYTOCVSU-UHFFFAOYSA-N 0.000 claims 2
- UZJGSDSVBBLIOE-UHFFFAOYSA-N 1,1-dimethyl-3-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]urea Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNC(=O)N(C)C)CCOCC1 UZJGSDSVBBLIOE-UHFFFAOYSA-N 0.000 claims 2
- HOPYAAZKATUIFK-UHFFFAOYSA-N 1-(2-methoxyethyl)-4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine Chemical compound C1CN(CCOC)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 HOPYAAZKATUIFK-UHFFFAOYSA-N 0.000 claims 2
- VGNXQHOEODSTIS-UHFFFAOYSA-N 1-[1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperidin-4-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1CCN(CC2(CCOCC2)C=2C=CC(OCCCN3CCCC3)=CC=2)CC1 VGNXQHOEODSTIS-UHFFFAOYSA-N 0.000 claims 2
- CKMCOHGSSZOEFB-UHFFFAOYSA-N 1-[3-[4-[4-(aziridin-1-ylmethyl)oxan-4-yl]phenoxy]propyl]pyrrolidine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2CC2)CCOCC1 CKMCOHGSSZOEFB-UHFFFAOYSA-N 0.000 claims 2
- QLGUCVUHRBZKBJ-UHFFFAOYSA-N 1-[3-[4-[4-(pyrrolidin-1-ylmethyl)oxan-4-yl]phenoxy]propyl]pyrrolidine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2CCCC2)CCOCC1 QLGUCVUHRBZKBJ-UHFFFAOYSA-N 0.000 claims 2
- KSKWZLNAKPWTKO-UHFFFAOYSA-N 1-[4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1C1(CN(C)C)CCOCC1 KSKWZLNAKPWTKO-UHFFFAOYSA-N 0.000 claims 2
- JBSFDDWFZFZDDB-UHFFFAOYSA-N 1-[4-[4-(1-cyclopentylpiperidin-4-yl)oxyphenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C=1C=C(OC2CCN(CC2)C2CCCC2)C=CC=1C1(CN(C)C)CCOCC1 JBSFDDWFZFZDDB-UHFFFAOYSA-N 0.000 claims 2
- VOPSNDOAKUPRDG-UHFFFAOYSA-N 1-[4-[4-(2,2-dimethyl-3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C=1C=C(OCC(C)(C)CN2CCCC2)C=CC=1C1(CN(C)C)CCOCC1 VOPSNDOAKUPRDG-UHFFFAOYSA-N 0.000 claims 2
- XNNCVYHLEUOQRR-UHFFFAOYSA-N 1-[4-[4-[(1-cyclopentylazetidin-3-yl)methoxy]phenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C=1C=C(OCC2CN(C2)C2CCCC2)C=CC=1C1(CN(C)C)CCOCC1 XNNCVYHLEUOQRR-UHFFFAOYSA-N 0.000 claims 2
- WKVBPGHCMKJTMI-UHFFFAOYSA-N 1-[4-[4-[3-(2,6-dimethylpiperidin-1-yl)propoxy]phenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound CC1CCCC(C)N1CCCOC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 WKVBPGHCMKJTMI-UHFFFAOYSA-N 0.000 claims 2
- GBUPICRCBCLNIO-UHFFFAOYSA-N 1-[4-[4-[3-[4-(2-methoxyethyl)piperidin-1-yl]propoxy]phenyl]oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C1CC(CCOC)CCN1CCCOC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 GBUPICRCBCLNIO-UHFFFAOYSA-N 0.000 claims 2
- RRNAXZZYYIHNEW-UHFFFAOYSA-N 1-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]pyrrolidin-2-one Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CN3C(CCC3)=O)CCOCC2)C=C1 RRNAXZZYYIHNEW-UHFFFAOYSA-N 0.000 claims 2
- ZLVSRJOAHRMXHL-UHFFFAOYSA-N 1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperidin-4-ol Chemical compound C1CC(O)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 ZLVSRJOAHRMXHL-UHFFFAOYSA-N 0.000 claims 2
- FIQWXWSGBVMDNA-UHFFFAOYSA-N 1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 FIQWXWSGBVMDNA-UHFFFAOYSA-N 0.000 claims 2
- DXXUHJZJMCJLNF-UHFFFAOYSA-N 1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyrrolidin-3-ol Chemical compound C1C(O)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 DXXUHJZJMCJLNF-UHFFFAOYSA-N 0.000 claims 2
- NYLMEHMJBYNUEM-UHFFFAOYSA-N 1-ethyl-4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine Chemical compound C1CN(CC)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 NYLMEHMJBYNUEM-UHFFFAOYSA-N 0.000 claims 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 2
- JBEXQSVUIAWYDP-UHFFFAOYSA-N 1-methyl-4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]-1,4-diazepane Chemical compound C1CN(C)CCCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 JBEXQSVUIAWYDP-UHFFFAOYSA-N 0.000 claims 2
- QMNCUFQWZHWXKU-UHFFFAOYSA-N 1-methyl-5-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1,2,4-triazole Chemical compound CN1N=CN=C1C1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 QMNCUFQWZHWXKU-UHFFFAOYSA-N 0.000 claims 2
- ZDUQUJOGTFLUAK-UHFFFAOYSA-N 1-propyl-4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine Chemical compound C1CN(CCC)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 ZDUQUJOGTFLUAK-UHFFFAOYSA-N 0.000 claims 2
- UOXUQDQCNSXUOO-UHFFFAOYSA-N 2-[1-[3-[4-[4-[(dimethylamino)methyl]oxan-4-yl]phenoxy]propyl]piperidin-4-yl]ethanol Chemical compound C=1C=C(OCCCN2CCC(CCO)CC2)C=CC=1C1(CN(C)C)CCOCC1 UOXUQDQCNSXUOO-UHFFFAOYSA-N 0.000 claims 2
- KNHSFKATHPWDQO-UHFFFAOYSA-N 2-[4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]oxan-4-yl]-4-methyl-1,3-thiazole Chemical compound CC1=CSC(C2(CCOCC2)C=2C=CC(OC3CCN(CC3)C3CCC3)=CC=2)=N1 KNHSFKATHPWDQO-UHFFFAOYSA-N 0.000 claims 2
- TYHBLYNUSIGTFN-UHFFFAOYSA-N 2-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]-1,3-thiazole Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C=2SC=CN=2)C=C1 TYHBLYNUSIGTFN-UHFFFAOYSA-N 0.000 claims 2
- UHZVIIOBIQKVRY-UHFFFAOYSA-N 2-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1,3-thiazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2SC=CN=2)CCOCC1 UHZVIIOBIQKVRY-UHFFFAOYSA-N 0.000 claims 2
- WGXSTPUZWKHHIN-UHFFFAOYSA-N 2-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1h-benzimidazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2NC3=CC=CC=C3N=2)CCOCC1 WGXSTPUZWKHHIN-UHFFFAOYSA-N 0.000 claims 2
- PAQDMRQSCIQKGH-UHFFFAOYSA-N 2-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1h-imidazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2NC=CN=2)CCOCC1 PAQDMRQSCIQKGH-UHFFFAOYSA-N 0.000 claims 2
- KTDFIVHCUKCTEI-UHFFFAOYSA-N 2-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]pyridine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2N=CC=CC=2)CCOCC1 KTDFIVHCUKCTEI-UHFFFAOYSA-N 0.000 claims 2
- FRGVRKFMMOOGSM-UHFFFAOYSA-N 2-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]-1,2-thiazolidine 1,1-dioxide Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CN3S(CCC3)(=O)=O)CCOCC2)C=C1 FRGVRKFMMOOGSM-UHFFFAOYSA-N 0.000 claims 2
- AVPCVWMHVORKGR-UHFFFAOYSA-N 2-[[methyl-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]amino]methyl]phenol Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)CN(C)CC1=CC=CC=C1O AVPCVWMHVORKGR-UHFFFAOYSA-N 0.000 claims 2
- AECLBENGQNXVFI-UHFFFAOYSA-N 2-phenyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]acetamide Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)CNC(=O)CC1=CC=CC=C1 AECLBENGQNXVFI-UHFFFAOYSA-N 0.000 claims 2
- GYYJBPDLLILVFL-UHFFFAOYSA-N 4,4-difluoro-1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperidine Chemical compound C1CC(F)(F)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 GYYJBPDLLILVFL-UHFFFAOYSA-N 0.000 claims 2
- VEEODXBIDFVFFG-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexan-1-ol Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)C)CCC(O)CC1 VEEODXBIDFVFFG-UHFFFAOYSA-N 0.000 claims 2
- MVNUXWMKWYRDPV-UHFFFAOYSA-N 4-[3-[4-[4-(morpholin-4-ylmethyl)oxan-4-yl]phenoxy]propyl]-1,4-oxazepane Chemical compound C1CCOCCN1CCCOC(C=C1)=CC=C1C1(CN2CCOCC2)CCOCC1 MVNUXWMKWYRDPV-UHFFFAOYSA-N 0.000 claims 2
- VUFVULVMLHASLR-UHFFFAOYSA-N 4-[3-[4-[4-(morpholin-4-ylmethyl)oxan-4-yl]phenoxy]propyl]morpholine Chemical compound C1COCCN1CCCOC(C=C1)=CC=C1C1(CN2CCOCC2)CCOCC1 VUFVULVMLHASLR-UHFFFAOYSA-N 0.000 claims 2
- KHYHAJFFKIMKIG-UHFFFAOYSA-N 4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-n-ethyloxane-4-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1C1(C(=O)NCC)CCOCC1 KHYHAJFFKIMKIG-UHFFFAOYSA-N 0.000 claims 2
- GPNMRNPCGBAHKE-UHFFFAOYSA-N 4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-n-methyloxane-4-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1C1(C(=O)NC)CCOCC1 GPNMRNPCGBAHKE-UHFFFAOYSA-N 0.000 claims 2
- CODXJUSRZZTCGH-UHFFFAOYSA-N 4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-n-propan-2-yloxane-4-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1C1(C(=O)NC(C)C)CCOCC1 CODXJUSRZZTCGH-UHFFFAOYSA-N 0.000 claims 2
- JZODFSBQEUGQMQ-UHFFFAOYSA-N 4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxane-4-carboxamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(C(=O)N)CCOCC1 JZODFSBQEUGQMQ-UHFFFAOYSA-N 0.000 claims 2
- MWAREQPBVUUGOT-UHFFFAOYSA-N 4-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]pyrimidine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2N=CN=CC=2)CCOCC1 MWAREQPBVUUGOT-UHFFFAOYSA-N 0.000 claims 2
- SKMQKONWPGHOBW-UHFFFAOYSA-N 4-[4-[4-(4,5-dimethyl-1h-imidazol-2-yl)oxan-4-yl]phenoxy]-1-propan-2-ylpiperidine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C=2NC(C)=C(C)N=2)C=C1 SKMQKONWPGHOBW-UHFFFAOYSA-N 0.000 claims 2
- LEILZRPZDQZFEE-UHFFFAOYSA-N 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methoxy]pyridine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(COC=2C=CN=CC=2)CCOCC1 LEILZRPZDQZFEE-UHFFFAOYSA-N 0.000 claims 2
- HPDOUXDZQOEYHL-UHFFFAOYSA-N 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]-1,2,4-triazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2C=NN=C2)CCOCC1 HPDOUXDZQOEYHL-UHFFFAOYSA-N 0.000 claims 2
- GPFPUDVCLGGWGZ-UHFFFAOYSA-N 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]-1,4-thiazinane 1-oxide Chemical compound C1CS(=O)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 GPFPUDVCLGGWGZ-UHFFFAOYSA-N 0.000 claims 2
- MRLGGOHDOBOICN-UHFFFAOYSA-N 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]morpholine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2CCOCC2)CCOCC1 MRLGGOHDOBOICN-UHFFFAOYSA-N 0.000 claims 2
- QUNUESAMZQXTKG-UHFFFAOYSA-N 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine-1-carboxamide Chemical compound C1CN(C(=O)N)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 QUNUESAMZQXTKG-UHFFFAOYSA-N 0.000 claims 2
- ZQFGZKLSGXKHJG-UHFFFAOYSA-N 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]thiomorpholine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2CCSCC2)CCOCC1 ZQFGZKLSGXKHJG-UHFFFAOYSA-N 0.000 claims 2
- UXWMAOFPYMFRPH-UHFFFAOYSA-N 4-[[4-[4-[(1-cyclobutylazetidin-3-yl)methoxy]phenyl]oxan-4-yl]methyl]morpholine Chemical compound C1N(C2CCC2)CC1COC(C=C1)=CC=C1C1(CN2CCOCC2)CCOCC1 UXWMAOFPYMFRPH-UHFFFAOYSA-N 0.000 claims 2
- KXPGLSRZENSMAL-UHFFFAOYSA-N 4-[[4-[4-[(1-propan-2-ylazetidin-3-yl)methoxy]phenyl]oxan-4-yl]methyl]morpholine Chemical compound C1N(C(C)C)CC1COC1=CC=C(C2(CN3CCOCC3)CCOCC2)C=C1 KXPGLSRZENSMAL-UHFFFAOYSA-N 0.000 claims 2
- WTXHACCTHOJKIM-UHFFFAOYSA-N 4-methyl-1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]imidazole Chemical compound C1=NC(C)=CN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 WTXHACCTHOJKIM-UHFFFAOYSA-N 0.000 claims 2
- RZPVVOMLCOYBCK-UHFFFAOYSA-N 4-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyridin-3-amine Chemical compound CC1=CC=NC=C1NCC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 RZPVVOMLCOYBCK-UHFFFAOYSA-N 0.000 claims 2
- FGYBEJQOSAANHP-UHFFFAOYSA-N 5-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1,3-oxazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2OC=NC=2)CCOCC1 FGYBEJQOSAANHP-UHFFFAOYSA-N 0.000 claims 2
- QDFWGDDYKKETPO-UHFFFAOYSA-N 5-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1h-imidazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2N=CNC=2)CCOCC1 QDFWGDDYKKETPO-UHFFFAOYSA-N 0.000 claims 2
- CPSRSPJNTLCEQG-UHFFFAOYSA-N 6-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2NC3=NC=CN=C3C=2)CCOCC1 CPSRSPJNTLCEQG-UHFFFAOYSA-N 0.000 claims 2
- VQCXXYLXFYBGPR-UHFFFAOYSA-N [4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]oxan-4-yl]-morpholin-4-ylmethanone Chemical compound C1COCCC1(C=1C=CC(OC2CCN(CC2)C2CCC2)=CC=1)C(=O)N1CCOCC1 VQCXXYLXFYBGPR-UHFFFAOYSA-N 0.000 claims 2
- OGCXURSQSNWCRM-UHFFFAOYSA-N [4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]-pyrrolidin-1-ylmethanone Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C(=O)N2CCCC2)C=C1 OGCXURSQSNWCRM-UHFFFAOYSA-N 0.000 claims 2
- ODKAOVAQZVVZHR-UHFFFAOYSA-N [4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methylurea Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNC(=O)N)CCOCC1 ODKAOVAQZVVZHR-UHFFFAOYSA-N 0.000 claims 2
- RBIPSPNAWFNPSZ-UHFFFAOYSA-N [4-[4-[(1-cyclobutylazetidin-3-yl)methoxy]phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCC2CN(C2)C2CCC2)C=CC=1C1(CN)CCOCC1 RBIPSPNAWFNPSZ-UHFFFAOYSA-N 0.000 claims 2
- CDHCVWBGOGPENG-UHFFFAOYSA-N [4-[4-[(1-propan-2-ylazetidin-3-yl)methoxy]phenyl]oxan-4-yl]methanamine Chemical compound C1N(C(C)C)CC1COC1=CC=C(C2(CN)CCOCC2)C=C1 CDHCVWBGOGPENG-UHFFFAOYSA-N 0.000 claims 2
- ICDRAGKOOXFLEP-UHFFFAOYSA-N [4-[4-[3-(azetidin-1-yl)propoxy]phenyl]oxan-4-yl]-morpholin-4-ylmethanone Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCC2)=CC=1)C(=O)N1CCOCC1 ICDRAGKOOXFLEP-UHFFFAOYSA-N 0.000 claims 2
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 2
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims 2
- CZQMLTXNUJFUBB-UHFFFAOYSA-N ethyl 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 CZQMLTXNUJFUBB-UHFFFAOYSA-N 0.000 claims 2
- XOWQZTPLRQPPPO-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(2-methyl-3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanamine Chemical compound C1CCCN1CC(C)COC(C=C1)=CC=C1C1(CN(C)C)CCOCC1 XOWQZTPLRQPPPO-UHFFFAOYSA-N 0.000 claims 2
- LDGDZTGHZBAUPM-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCN(C)CC2)C=CC=1C1(CN(C)C)CCOCC1 LDGDZTGHZBAUPM-UHFFFAOYSA-N 0.000 claims 2
- HJHVMUYSFUASLH-UHFFFAOYSA-N n-[[4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]pyridin-3-amine Chemical compound C1COCCC1(C=1C=CC(OC2CCN(CC2)C2CCC2)=CC=1)CNC1=CC=CN=C1 HJHVMUYSFUASLH-UHFFFAOYSA-N 0.000 claims 2
- WNAYFOWARZTSDJ-UHFFFAOYSA-N n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]acetamide Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CNC(C)=O)CCOCC2)C=C1 WNAYFOWARZTSDJ-UHFFFAOYSA-N 0.000 claims 2
- QATRFQUNMTWIDH-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]acetamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNC(=O)C)CCOCC1 QATRFQUNMTWIDH-UHFFFAOYSA-N 0.000 claims 2
- WDTNBFRVGJBSQP-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNCC)CCOCC1 WDTNBFRVGJBSQP-UHFFFAOYSA-N 0.000 claims 2
- NLALIZGTNRUBCV-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]methanesulfonamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNS(=O)(=O)C)CCOCC1 NLALIZGTNRUBCV-UHFFFAOYSA-N 0.000 claims 2
- QLYRYWSPLSLJFP-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]phthalazin-1-amine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CNC=2C3=CC=CC=C3C=NN=2)CCOCC1 QLYRYWSPLSLJFP-UHFFFAOYSA-N 0.000 claims 2
- JEJPEPIBEXOLTR-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyridazin-4-amine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CNC=2C=NN=CC=2)CCOCC1 JEJPEPIBEXOLTR-UHFFFAOYSA-N 0.000 claims 2
- JLLFNUFCXVUHTO-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyridin-2-amine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CNC=2N=CC=CC=2)CCOCC1 JLLFNUFCXVUHTO-UHFFFAOYSA-N 0.000 claims 2
- FOUOYEGGGDXMMO-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyridin-3-amine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CNC=2C=NC=CC=2)CCOCC1 FOUOYEGGGDXMMO-UHFFFAOYSA-N 0.000 claims 2
- JLFZDLPUMPMLHK-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyrimidin-4-amine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CNC=2N=CN=CC=2)CCOCC1 JLFZDLPUMPMLHK-UHFFFAOYSA-N 0.000 claims 2
- CWSXWEJHQKNTLI-UHFFFAOYSA-N n-[[4-[4-(3-thiomorpholin-4-ylpropoxy)phenyl]oxan-4-yl]methyl]acetamide Chemical compound C=1C=C(OCCCN2CCSCC2)C=CC=1C1(CNC(=O)C)CCOCC1 CWSXWEJHQKNTLI-UHFFFAOYSA-N 0.000 claims 2
- BUJRSYHLXZSYHD-UHFFFAOYSA-N n-[[4-[4-(3-thiomorpholin-4-ylpropoxy)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound C=1C=C(OCCCN2CCSCC2)C=CC=1C1(CNCC)CCOCC1 BUJRSYHLXZSYHD-UHFFFAOYSA-N 0.000 claims 2
- QPNILOYHSDCBDT-UHFFFAOYSA-N n-[[4-[4-[3-[cyclobutyl(methyl)amino]propoxy]phenyl]oxan-4-yl]methyl]pyridin-2-amine Chemical compound C1CCC1N(C)CCCOC(C=C1)=CC=C1C1(CNC=2N=CC=CC=2)CCOCC1 QPNILOYHSDCBDT-UHFFFAOYSA-N 0.000 claims 2
- BTAOKUXGKDKTIR-UHFFFAOYSA-N n-ethyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]acetamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(CC)C(C)=O)CCOCC1 BTAOKUXGKDKTIR-UHFFFAOYSA-N 0.000 claims 2
- SRCQJMNVJQHBMX-UHFFFAOYSA-N n-ethyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(CC)CC)CCOCC1 SRCQJMNVJQHBMX-UHFFFAOYSA-N 0.000 claims 2
- UFPZLRWJGHLQBS-UHFFFAOYSA-N n-ethyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]methanesulfonamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(CC)S(C)(=O)=O)CCOCC1 UFPZLRWJGHLQBS-UHFFFAOYSA-N 0.000 claims 2
- BBNBUZYCFCDDIZ-UHFFFAOYSA-N n-ethyl-n-methyl-4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxane-4-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C=CC=1C1(C(=O)N(C)CC)CCOCC1 BBNBUZYCFCDDIZ-UHFFFAOYSA-N 0.000 claims 2
- HOTBGMJHICUUFX-UHFFFAOYSA-N n-methyl-1-[4-[4-(3-morpholin-4-ylpropoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCOCC2)C=CC=1C1(CNC)CCOCC1 HOTBGMJHICUUFX-UHFFFAOYSA-N 0.000 claims 2
- XSMXKVJARRFDRB-UHFFFAOYSA-N n-methyl-4-[4-(3-morpholin-4-ylpropoxy)phenyl]oxane-4-carboxamide Chemical compound C=1C=C(OCCCN2CCOCC2)C=CC=1C1(C(=O)NC)CCOCC1 XSMXKVJARRFDRB-UHFFFAOYSA-N 0.000 claims 2
- MVRWBUZTUBNFBF-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]butan-1-amine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)CCCC)CCOCC1 MVRWBUZTUBNFBF-UHFFFAOYSA-N 0.000 claims 2
- XEGYAIKLKDBMDR-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]cyclopropanamine Chemical compound C1CC1N(C)CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 XEGYAIKLKDBMDR-UHFFFAOYSA-N 0.000 claims 2
- XSXZDTPDFZRWPH-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)CC)CCOCC1 XSXZDTPDFZRWPH-UHFFFAOYSA-N 0.000 claims 2
- MBKWUJCCNNCUNO-UHFFFAOYSA-N piperazin-1-yl-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)C(=O)N1CCNCC1 MBKWUJCCNNCUNO-UHFFFAOYSA-N 0.000 claims 2
- WZBLDNYPIYIMAA-UHFFFAOYSA-N piperidin-1-yl-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)C(=O)N1CCCCC1 WZBLDNYPIYIMAA-UHFFFAOYSA-N 0.000 claims 2
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 claims 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 2
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 claims 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 claims 1
- MWEHDKCCEDBLSI-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1CN(CC)CCN1C(=O)C1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 MWEHDKCCEDBLSI-UHFFFAOYSA-N 0.000 claims 1
- OPKPPUJMSDPOIQ-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methanone Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C(=O)N2CCN(C)CC2)C=C1 OPKPPUJMSDPOIQ-UHFFFAOYSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 claims 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 claims 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 claims 1
- IVKMZVKZBRTJMK-UHFFFAOYSA-N 1-[4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 IVKMZVKZBRTJMK-UHFFFAOYSA-N 0.000 claims 1
- OLYNPHATHQNKST-UHFFFAOYSA-N 1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]imidazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CN2C=NC=C2)CCOCC1 OLYNPHATHQNKST-UHFFFAOYSA-N 0.000 claims 1
- RKRUGRFQMMFERN-UHFFFAOYSA-N 1-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]benzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2N(C)C=1NCC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 RKRUGRFQMMFERN-UHFFFAOYSA-N 0.000 claims 1
- UVWLZHYBGQQCFF-UHFFFAOYSA-N 2-[4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]oxan-4-yl]-1,3-thiazole Chemical compound C1CCC1N1CCC(OC=2C=CC(=CC=2)C2(CCOCC2)C=2SC=CN=2)CC1 UVWLZHYBGQQCFF-UHFFFAOYSA-N 0.000 claims 1
- HQVSSJJFQDIZQV-UHFFFAOYSA-N 2-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1,3,4-oxadiazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C=2OC=NN=2)CCOCC1 HQVSSJJFQDIZQV-UHFFFAOYSA-N 0.000 claims 1
- XJKWSXKURSPHDZ-UHFFFAOYSA-N 2-methyl-1-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]imidazo[4,5-c]pyridine Chemical compound CC1=NC2=CN=CC=C2N1CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 XJKWSXKURSPHDZ-UHFFFAOYSA-N 0.000 claims 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 claims 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 claims 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 claims 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 claims 1
- HRYIZCYQTOVMBN-UHFFFAOYSA-N 4-[[4-[4-[3-(azetidin-1-yl)propoxy]phenyl]oxan-4-yl]methyl]morpholine Chemical compound C1CCN1CCCOC(C=C1)=CC=C1C1(CN2CCOCC2)CCOCC1 HRYIZCYQTOVMBN-UHFFFAOYSA-N 0.000 claims 1
- KQADTJYCJUHZMG-UHFFFAOYSA-N 4-methyl-2-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1,3-thiazole Chemical compound CC1=CSC(C2(CCOCC2)C=2C=CC(OCCCN3CCCC3)=CC=2)=N1 KQADTJYCJUHZMG-UHFFFAOYSA-N 0.000 claims 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 claims 1
- RNNAUIFCSDAYCV-UHFFFAOYSA-N 5-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]-1h-1,2,4-triazole Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(C2=NNC=N2)CCOCC1 RNNAUIFCSDAYCV-UHFFFAOYSA-N 0.000 claims 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 claims 1
- PBMATHZIIODXOD-UHFFFAOYSA-N N-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]oxane-4-carboxamide Chemical compound O1CCC(CC1)C(=O)NC1=CC=C(C=C1)OC1CCN(CC1)C1CCC1 PBMATHZIIODXOD-UHFFFAOYSA-N 0.000 claims 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 claims 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 claims 1
- BIVBUDNGTIUETR-UHFFFAOYSA-N azetidin-1-yl-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)C(=O)N1CCC1 BIVBUDNGTIUETR-UHFFFAOYSA-N 0.000 claims 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- POWVWLMVEFPQEN-UHFFFAOYSA-N morpholin-4-yl-[4-[4-(3-morpholin-4-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCOCC2)=CC=1)C(=O)N1CCOCC1 POWVWLMVEFPQEN-UHFFFAOYSA-N 0.000 claims 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 claims 1
- RRQFVZARNCCUSF-UHFFFAOYSA-N n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]pyridin-3-amine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CNC=3C=NC=CC=3)CCOCC2)C=C1 RRQFVZARNCCUSF-UHFFFAOYSA-N 0.000 claims 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 claims 1
- GPSDRLSGZYVTNX-UHFFFAOYSA-N n-ethyl-n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]acetamide Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C=CC=1C1(CN(CC)C(C)=O)CCOCC1 GPSDRLSGZYVTNX-UHFFFAOYSA-N 0.000 claims 1
- JZCNSIUCQNIGPA-UHFFFAOYSA-N n-ethyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]ethanesulfonamide Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(CC)S(=O)(=O)CC)CCOCC1 JZCNSIUCQNIGPA-UHFFFAOYSA-N 0.000 claims 1
- OKTIWHCNMWUMDS-UHFFFAOYSA-N n-methyl-n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]propanamide Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C=CC=1C1(CN(C)C(=O)CC)CCOCC1 OKTIWHCNMWUMDS-UHFFFAOYSA-N 0.000 claims 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 610
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 372
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 267
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 164
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 161
- 239000000203 mixture Substances 0.000 description 158
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 153
- 239000000243 solution Substances 0.000 description 149
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 122
- 238000006243 chemical reaction Methods 0.000 description 103
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 95
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
- 239000007787 solid Substances 0.000 description 80
- 239000011541 reaction mixture Substances 0.000 description 73
- 239000003921 oil Substances 0.000 description 70
- 235000019198 oils Nutrition 0.000 description 70
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- 238000004440 column chromatography Methods 0.000 description 54
- 235000019439 ethyl acetate Nutrition 0.000 description 54
- 239000000377 silicon dioxide Substances 0.000 description 52
- 239000000543 intermediate Substances 0.000 description 50
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 49
- 239000002904 solvent Substances 0.000 description 45
- 239000000741 silica gel Substances 0.000 description 44
- 229910002027 silica gel Inorganic materials 0.000 description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 43
- 239000011734 sodium Substances 0.000 description 40
- 239000000284 extract Substances 0.000 description 39
- 238000010992 reflux Methods 0.000 description 38
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 36
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 36
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 34
- 238000003756 stirring Methods 0.000 description 34
- 239000002585 base Substances 0.000 description 31
- 238000009472 formulation Methods 0.000 description 31
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- 239000003480 eluent Substances 0.000 description 28
- 239000008346 aqueous phase Substances 0.000 description 27
- 229920006395 saturated elastomer Polymers 0.000 description 27
- 239000000725 suspension Substances 0.000 description 27
- 238000004587 chromatography analysis Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- 239000010410 layer Substances 0.000 description 25
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 24
- 239000012043 crude product Substances 0.000 description 24
- 239000012267 brine Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 20
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 20
- VWIQFPCPQASXPQ-UHFFFAOYSA-N 4-[4-[(dimethylamino)methyl]oxan-4-yl]phenol Chemical compound C=1C=C(O)C=CC=1C1(CN(C)C)CCOCC1 VWIQFPCPQASXPQ-UHFFFAOYSA-N 0.000 description 19
- 239000012299 nitrogen atmosphere Substances 0.000 description 19
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 19
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 15
- 239000013058 crude material Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 229910010082 LiAlH Inorganic materials 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 239000000538 analytical sample Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 9
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 229910021529 ammonia Inorganic materials 0.000 description 8
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 8
- WNJPEDPHRPKFEW-HDICACEKSA-N 4-[4-[3-[(2s,5r)-2,5-dimethylpyrrolidin-1-yl]propoxy]phenyl]oxane-4-carbonitrile Chemical compound C[C@H]1CC[C@@H](C)N1CCCOC1=CC=C(C2(CCOCC2)C#N)C=C1 WNJPEDPHRPKFEW-HDICACEKSA-N 0.000 description 7
- JIGYQYPDFHZOAO-UHFFFAOYSA-N [4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN)CCOCC1 JIGYQYPDFHZOAO-UHFFFAOYSA-N 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 238000007429 general method Methods 0.000 description 7
- UQQFZGZYSHEGJU-UHFFFAOYSA-N 1-[4-(3-chloropropoxy)phenyl]cyclohexane-1-carbonitrile Chemical compound C1=CC(OCCCCl)=CC=C1C1(C#N)CCCCC1 UQQFZGZYSHEGJU-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 230000002152 alkylating effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 239000002027 dichloromethane extract Substances 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002808 molecular sieve Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- ZDEQFCJOJLVAAS-UHFFFAOYSA-N 1-[4-(3-bromopropoxy)phenyl]cyclohexane-1-carbonitrile Chemical compound C1=CC(OCCCBr)=CC=C1C1(C#N)CCCCC1 ZDEQFCJOJLVAAS-UHFFFAOYSA-N 0.000 description 5
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 5
- XNZYWQLJSNAVBI-UHFFFAOYSA-N 2-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1OCCCN1CCCC1 XNZYWQLJSNAVBI-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000005909 Kieselgur Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 125000003158 alcohol group Chemical group 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- SPRTXTPFQKHSBG-UHFFFAOYSA-N 1-(3-chloropropyl)pyrrolidine Chemical compound ClCCCN1CCCC1 SPRTXTPFQKHSBG-UHFFFAOYSA-N 0.000 description 4
- OFLQDYJSAAJMIQ-UHFFFAOYSA-N 4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxane-4-carbaldehyde Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(C=O)CCOCC1 OFLQDYJSAAJMIQ-UHFFFAOYSA-N 0.000 description 4
- GGQDDRZCQPULDP-UHFFFAOYSA-N 4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxane-4-carbonitrile Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(C#N)CCOCC1 GGQDDRZCQPULDP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- KUJRCHAJUOPQGL-UHFFFAOYSA-N dimethyl 4-cyano-4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]heptanedioate Chemical compound C1=CC(C(CCC(=O)OC)(C#N)CCC(=O)OC)=CC=C1OCCCN1CCCC1 KUJRCHAJUOPQGL-UHFFFAOYSA-N 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- IGWPRBLYGRKDHE-UHFFFAOYSA-N methyl 5-cyano-2-oxo-5-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexane-1-carboxylate Chemical compound C1CC(=O)C(C(=O)OC)CC1(C#N)C(C=C1)=CC=C1OCCCN1CCCC1 IGWPRBLYGRKDHE-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000010802 sludge Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- OVIMJSZZOHOTTP-UHFFFAOYSA-N (1-cyclopentylpiperidin-4-yl) methanesulfonate Chemical compound C1CC(OS(=O)(=O)C)CCN1C1CCCC1 OVIMJSZZOHOTTP-UHFFFAOYSA-N 0.000 description 3
- BMHBIUFOQLWXDJ-UHFFFAOYSA-N (1-propan-2-ylpiperidin-4-yl) methanesulfonate Chemical compound CC(C)N1CCC(OS(C)(=O)=O)CC1 BMHBIUFOQLWXDJ-UHFFFAOYSA-N 0.000 description 3
- ZEBFPAXSQXIPNF-OLQVQODUSA-N (2r,5s)-2,5-dimethylpyrrolidine Chemical compound C[C@H]1CC[C@@H](C)N1 ZEBFPAXSQXIPNF-OLQVQODUSA-N 0.000 description 3
- NXCPQWURTFLLSV-UHFFFAOYSA-N 1-chloro-2-(2-chlorophenoxy)peroxybenzene Chemical compound ClC1=C(OOOC2=C(C=CC=C2)Cl)C=CC=C1 NXCPQWURTFLLSV-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- AXHPPYBBIPUZEB-UHFFFAOYSA-N 3-[4-[(dimethylamino)methyl]oxan-4-yl]phenol Chemical compound C=1C=CC(O)=CC=1C1(CN(C)C)CCOCC1 AXHPPYBBIPUZEB-UHFFFAOYSA-N 0.000 description 3
- FKCMGWYAPOCAKE-UHFFFAOYSA-N 3-pyrrolidin-1-ylbutan-1-ol Chemical compound OCCC(C)N1CCCC1 FKCMGWYAPOCAKE-UHFFFAOYSA-N 0.000 description 3
- CXGROXURTMZSEK-UHFFFAOYSA-N 4-(4-hydroxyphenyl)oxane-4-carbonitrile Chemical compound C1=CC(O)=CC=C1C1(C#N)CCOCC1 CXGROXURTMZSEK-UHFFFAOYSA-N 0.000 description 3
- AEDAKKUAAMXNOA-UHFFFAOYSA-N 4-(4-methoxyphenyl)oxane-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1(C#N)CCOCC1 AEDAKKUAAMXNOA-UHFFFAOYSA-N 0.000 description 3
- KNQFPBXFDMVEHL-UHFFFAOYSA-N 4-oxo-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexane-1-carbonitrile Chemical compound C1CC(=O)CCC1(C#N)C(C=C1)=CC=C1OCCCN1CCCC1 KNQFPBXFDMVEHL-UHFFFAOYSA-N 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000030663 Libido disease Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- CHPRFKYDQRKRRK-ZCFIWIBFSA-N (2r)-2-(methoxymethyl)pyrrolidine Chemical compound COC[C@H]1CCCN1 CHPRFKYDQRKRRK-ZCFIWIBFSA-N 0.000 description 2
- VOGQZKPKCZDFBF-AOOOYVTPSA-N (2r,6s)-1-(3-chloropropyl)-2,6-dimethylpiperidine Chemical compound C[C@H]1CCC[C@@H](C)N1CCCCl VOGQZKPKCZDFBF-AOOOYVTPSA-N 0.000 description 2
- UGRJIHHEPMVYEN-IUCAKERBSA-N (2s,5s)-1-(3-chloropropyl)-2,5-dimethylpyrrolidine Chemical compound C[C@H]1CC[C@H](C)N1CCCCl UGRJIHHEPMVYEN-IUCAKERBSA-N 0.000 description 2
- BWRWNUQAQPAYCK-RXMQYKEDSA-N (3r)-3-methoxypyrrolidine Chemical compound CO[C@@H]1CCNC1 BWRWNUQAQPAYCK-RXMQYKEDSA-N 0.000 description 2
- BWRWNUQAQPAYCK-YFKPBYRVSA-N (3s)-3-methoxypyrrolidine Chemical compound CO[C@H]1CCNC1 BWRWNUQAQPAYCK-YFKPBYRVSA-N 0.000 description 2
- AYKYOOPFBCOXSL-UHFFFAOYSA-N (4-hydroxyphenyl)acetonitrile Chemical compound OC1=CC=C(CC#N)C=C1 AYKYOOPFBCOXSL-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- RGHPCLZJAFCTIK-RXMQYKEDSA-N (R)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1 RGHPCLZJAFCTIK-RXMQYKEDSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- RMGFLMXDCGQKPS-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine Chemical compound ClCCN1CCCC1 RMGFLMXDCGQKPS-UHFFFAOYSA-N 0.000 description 2
- DRZVVYABPNLAOE-UHFFFAOYSA-N 1-(3-chloro-2-methylpropyl)pyrrolidine Chemical compound ClCC(C)CN1CCCC1 DRZVVYABPNLAOE-UHFFFAOYSA-N 0.000 description 2
- BAKHPYGIWRQPMS-UHFFFAOYSA-N 1-(3-chloropropyl)-2-methylpyrrolidine Chemical compound CC1CCCN1CCCCl BAKHPYGIWRQPMS-UHFFFAOYSA-N 0.000 description 2
- ADLTVEOBDGHJHS-UHFFFAOYSA-N 1-(3-chloropropyl)piperidin-4-ol Chemical compound OC1CCN(CCCCl)CC1 ADLTVEOBDGHJHS-UHFFFAOYSA-N 0.000 description 2
- MXDUNEZULWZDPP-UHFFFAOYSA-N 1-(4-hydroxyphenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC(O)=CC=C1C1(C#N)CCCCC1 MXDUNEZULWZDPP-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- ZCPKJYRSWUAKQK-UHFFFAOYSA-N 1-[4-(4-methoxyphenyl)oxan-4-yl]-n,n-dimethylmethanamine Chemical compound C1=CC(OC)=CC=C1C1(CN(C)C)CCOCC1 ZCPKJYRSWUAKQK-UHFFFAOYSA-N 0.000 description 2
- LXYFMMCUCYSWRF-JOCHJYFZSA-N 1-[[4-[4-[3-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]oxan-4-yl]methyl]-1,3,3-trimethylurea Chemical compound C1[C@H](N(C)C)CCN1CCCOC1=CC=C(C2(CN(C)C(=O)N(C)C)CCOCC2)C=C1 LXYFMMCUCYSWRF-JOCHJYFZSA-N 0.000 description 2
- MXXPDLJKKIHIGY-UHFFFAOYSA-N 1-benzyl-2,2-dimethylpyrrolidine Chemical compound CC1(C)CCCN1CC1=CC=CC=C1 MXXPDLJKKIHIGY-UHFFFAOYSA-N 0.000 description 2
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 2
- KJMYBDCXKKGIHT-UHFFFAOYSA-N 1-cyclopentylpiperidin-4-ol Chemical compound C1CC(O)CCN1C1CCCC1 KJMYBDCXKKGIHT-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- OVTMCBIZTDPCGB-UHFFFAOYSA-N 2,2-dimethyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound OCC(C)(C)CN1CCCC1 OVTMCBIZTDPCGB-UHFFFAOYSA-N 0.000 description 2
- PHODFIDDEBEGCS-UHFFFAOYSA-N 2,2-dimethylpyrrolidine Chemical compound CC1(C)CCCN1 PHODFIDDEBEGCS-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- LMGSBYGUGOVCNH-UHFFFAOYSA-N 4-(2-methoxyethyl)piperidine;hydrochloride Chemical compound Cl.COCCC1CCNCC1 LMGSBYGUGOVCNH-UHFFFAOYSA-N 0.000 description 2
- TZEFMWJJVMZXLM-UHFFFAOYSA-N 4-(3-chloropropyl)thiomorpholine Chemical compound ClCCCN1CCSCC1 TZEFMWJJVMZXLM-UHFFFAOYSA-N 0.000 description 2
- MSNKLEMTHNAVNT-UHFFFAOYSA-N 4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxane-4-carboxylic acid Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(C(=O)O)CCOCC1 MSNKLEMTHNAVNT-UHFFFAOYSA-N 0.000 description 2
- KBNHFWZYCVAENZ-UHFFFAOYSA-N 4-[4-(3-thiomorpholin-4-ylpropoxy)phenyl]oxane-4-carbonitrile Chemical compound C=1C=C(OCCCN2CCSCC2)C=CC=1C1(C#N)CCOCC1 KBNHFWZYCVAENZ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 208000030431 Male orgasmic disease Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- PZRIAMKUTUWBIB-UHFFFAOYSA-N N-methyl-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexan-1-amine Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCCCC1)NC PZRIAMKUTUWBIB-UHFFFAOYSA-N 0.000 description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000027520 Somatoform disease Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- VCRKYGDZXSUHJM-UHFFFAOYSA-N [4-(3-methoxyphenyl)oxan-4-yl]methanamine Chemical compound COC1=CC=CC(C2(CN)CCOCC2)=C1 VCRKYGDZXSUHJM-UHFFFAOYSA-N 0.000 description 2
- UEXNBAKMACUHKK-UHFFFAOYSA-N [4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanol Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CO)CCOCC1 UEXNBAKMACUHKK-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- VBWIZSYFQSOUFQ-UHFFFAOYSA-N cyclohexanecarbonitrile Chemical compound N#CC1CCCCC1 VBWIZSYFQSOUFQ-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000142 dyskinetic effect Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- XOHFSJRAEGVBNY-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylbutanoate Chemical compound CCOC(=O)CC(C)N1CCCC1 XOHFSJRAEGVBNY-UHFFFAOYSA-N 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- 239000003396 histamine H4 receptor antagonist Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 201000000068 inhibited male orgasm Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- 208000015421 male orgasm disease Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 229940050176 methyl chloride Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000003901 neurotransmitter uptake inhibitor Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- MZXZKBRQYRYOPD-UHFFFAOYSA-N tert-butyl n-[[1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexyl]methyl]carbamate Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNC(=O)OC(C)(C)C)CCCCC1 MZXZKBRQYRYOPD-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- 229960000607 ziprasidone Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SDGKUVSVPIIUCF-KNVOCYPGSA-N (2r,6s)-2,6-dimethylpiperidine Chemical compound C[C@H]1CCC[C@@H](C)N1 SDGKUVSVPIIUCF-KNVOCYPGSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- CRHQFEJXCQBQFB-HSZRJFAPSA-N (3r)-1-[3-[4-[4-[[2-methoxyethyl(methyl)amino]methyl]oxan-4-yl]phenoxy]propyl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C=1C=C(OCCCN2C[C@@H](CC2)N(C)C)C=CC=1C1(CN(C)CCOC)CCOCC1 CRHQFEJXCQBQFB-HSZRJFAPSA-N 0.000 description 1
- QTKGPIMTYKXKPS-GFCCVEGCSA-N (3r)-1-benzyl-3-methoxypyrrolidine Chemical compound C1[C@H](OC)CCN1CC1=CC=CC=C1 QTKGPIMTYKXKPS-GFCCVEGCSA-N 0.000 description 1
- RGZPOGDRXRCCRL-HXUWFJFHSA-N (3r)-n,n-dimethyl-1-[3-[4-[4-(methylaminomethyl)oxan-4-yl]phenoxy]propyl]pyrrolidin-3-amine Chemical compound C=1C=C(OCCCN2C[C@@H](CC2)N(C)C)C=CC=1C1(CNC)CCOCC1 RGZPOGDRXRCCRL-HXUWFJFHSA-N 0.000 description 1
- WZSQLNMWFQNOMF-HSZRJFAPSA-N (3r)-n,n-dimethyl-1-[3-[4-[4-(morpholin-4-ylmethyl)oxan-4-yl]phenoxy]propyl]pyrrolidin-3-amine Chemical compound C1[C@H](N(C)C)CCN1CCCOC1=CC=C(C2(CN3CCOCC3)CCOCC2)C=C1 WZSQLNMWFQNOMF-HSZRJFAPSA-N 0.000 description 1
- FOETXFLONXERFX-ZETCQYMHSA-N (3s)-1-tert-butylpyrrolidin-3-ol Chemical compound CC(C)(C)N1CC[C@H](O)C1 FOETXFLONXERFX-ZETCQYMHSA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- 125000005859 (C1-C6)alkanoyloxymethyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CHPRFKYDQRKRRK-LURJTMIESA-N (S)-2-(methoxymethyl)pyrrolidine Chemical compound COC[C@@H]1CCCN1 CHPRFKYDQRKRRK-LURJTMIESA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- FEWCLOYEKKAASN-UHFFFAOYSA-N 1-(3-chloropropyl)-2-methylpyrrolidine 2-methylpyrrolidine Chemical compound CC1NCCC1.ClCCCN1C(CCC1)C FEWCLOYEKKAASN-UHFFFAOYSA-N 0.000 description 1
- RLWKICJEUDCTGB-UHFFFAOYSA-N 1-(3-chloropropyl)-4-(2-methoxyethyl)piperidine Chemical compound COCCC1CCN(CCCCl)CC1 RLWKICJEUDCTGB-UHFFFAOYSA-N 0.000 description 1
- QGBHLZYTJCPHQW-UHFFFAOYSA-N 1-(3-chloropropyl)-4-methoxypiperidine Chemical compound COC1CCN(CCCCl)CC1 QGBHLZYTJCPHQW-UHFFFAOYSA-N 0.000 description 1
- QZBFMMABVFALNG-UHFFFAOYSA-N 1-(3-chloropropyl)piperidin-4-ol piperidin-4-ol Chemical compound OC1CCNCC1.ClCCCN1CCC(CC1)O QZBFMMABVFALNG-UHFFFAOYSA-N 0.000 description 1
- HDDNBUNZJIQDBQ-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine Chemical compound ClCCCN1CCCCC1 HDDNBUNZJIQDBQ-UHFFFAOYSA-N 0.000 description 1
- NUZOTFHVKGPADM-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine-4-carboxamide Chemical compound NC(=O)C1CCN(CCCCl)CC1 NUZOTFHVKGPADM-UHFFFAOYSA-N 0.000 description 1
- UDTFYMFVZKCITO-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine-4-carboxamide piperidine-4-carboxamide Chemical compound N1CCC(CC1)C(=O)N.ClCCCN1CCC(CC1)C(=O)N UDTFYMFVZKCITO-UHFFFAOYSA-N 0.000 description 1
- QXAVGTFIVOZYQY-UHFFFAOYSA-N 1-(3-chloropropyl)pyrrolidine pyrrolidine Chemical compound N1CCCC1.ClCCCN1CCCC1 QXAVGTFIVOZYQY-UHFFFAOYSA-N 0.000 description 1
- SQEQBYLFGAOUGK-UHFFFAOYSA-N 1-(4-chlorobutan-2-yl)pyrrolidine Chemical compound ClCCC(C)N1CCCC1 SQEQBYLFGAOUGK-UHFFFAOYSA-N 0.000 description 1
- OXQGAEALXILESC-UHFFFAOYSA-N 1-(4-chlorobutan-2-yl)pyrrolidine;hydrochloride Chemical compound Cl.ClCCC(C)N1CCCC1 OXQGAEALXILESC-UHFFFAOYSA-N 0.000 description 1
- YQXUSXSQFVWPRQ-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1(C#N)CCCCC1 YQXUSXSQFVWPRQ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FJNLUEKECMJPEL-UHFFFAOYSA-N 1-[3-[4-[4-(pyrrolidin-1-ylmethyl)oxan-4-yl]phenoxy]propyl]pyrrolidine 4-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]morpholine Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1CCOCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1CCCC1 FJNLUEKECMJPEL-UHFFFAOYSA-N 0.000 description 1
- SXJFAJJSPKVMAN-UHFFFAOYSA-N 1-[3-[4-[4-[(dimethylsulfamoylamino)methyl]oxan-4-yl]phenoxy]propyl]pyrrolidine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNS(=O)(=O)N(C)C)CCOCC1 SXJFAJJSPKVMAN-UHFFFAOYSA-N 0.000 description 1
- DHQBFBLWHSZLPY-UHFFFAOYSA-N 1-[4-(3-methoxyphenyl)oxan-4-yl]-n,n-dimethylmethanamine Chemical compound COC1=CC=CC(C2(CN(C)C)CCOCC2)=C1 DHQBFBLWHSZLPY-UHFFFAOYSA-N 0.000 description 1
- YJPDOIPIOIUSCV-UHFFFAOYSA-N 1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclopentane-1-carbonitrile Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(C#N)CCCC1 YJPDOIPIOIUSCV-UHFFFAOYSA-N 0.000 description 1
- KLJGWSWCIHJNGM-HXUWFJFHSA-N 1-[4-[3-[(3r)-3-methoxypyrrolidin-1-yl]propoxy]phenyl]cyclohexane-1-carbonitrile Chemical compound C1[C@H](OC)CCN1CCCOC1=CC=C(C2(CCCCC2)C#N)C=C1 KLJGWSWCIHJNGM-HXUWFJFHSA-N 0.000 description 1
- KLJGWSWCIHJNGM-FQEVSTJZSA-N 1-[4-[3-[(3s)-3-methoxypyrrolidin-1-yl]propoxy]phenyl]cyclohexane-1-carbonitrile Chemical compound C1[C@@H](OC)CCN1CCCOC1=CC=C(C2(CCCCC2)C#N)C=C1 KLJGWSWCIHJNGM-FQEVSTJZSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- ZKDOQFPDSUOLGF-UHFFFAOYSA-N 1-bromo-3-chloro-2-methylpropane Chemical compound ClCC(C)CBr ZKDOQFPDSUOLGF-UHFFFAOYSA-N 0.000 description 1
- NKSPFSPQDGGUIP-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]methanamine Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)CN(C)CC1CCCCC1 NKSPFSPQDGGUIP-UHFFFAOYSA-N 0.000 description 1
- OLICAVOABHZGDE-UHFFFAOYSA-N 1-cyclopentyl-n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]methanamine Chemical compound C1COCCC1(C=1C=CC(OCCCN2CCCC2)=CC=1)CN(C)CC1CCCC1 OLICAVOABHZGDE-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PNPJJNPAAUMVJK-UHFFFAOYSA-N 1-piperidin-4-ylpyrrolidin-2-one;hydrochloride Chemical compound Cl.O=C1CCCN1C1CCNCC1 PNPJJNPAAUMVJK-UHFFFAOYSA-N 0.000 description 1
- UZRXHHMTKCJKTQ-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-ol Chemical compound CC(C)N1CCC(O)CC1 UZRXHHMTKCJKTQ-UHFFFAOYSA-N 0.000 description 1
- BUGNITMKWYOPCU-UHFFFAOYSA-N 1-propylpiperidin-4-ol Chemical compound CCCN1CCC(O)CC1 BUGNITMKWYOPCU-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FYVMBPXFPFAECB-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanol Chemical compound CN1CCCC1CCO FYVMBPXFPFAECB-UHFFFAOYSA-N 0.000 description 1
- CLVNTYZKUHNUEF-UHFFFAOYSA-N 2-(2-chloroethyl)-1-methylpyrrolidine Chemical compound CN1CCCC1CCCl CLVNTYZKUHNUEF-UHFFFAOYSA-N 0.000 description 1
- LXKNAUOWEJWGTE-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(CC#N)=C1 LXKNAUOWEJWGTE-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- PACGLQCRGWFBJH-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C=C1 PACGLQCRGWFBJH-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- DGTVTTNTHLZNST-UHFFFAOYSA-N 2-[1-(3-chloropropyl)piperidin-4-yl]ethanol Chemical compound OCCC1CCN(CCCCl)CC1 DGTVTTNTHLZNST-UHFFFAOYSA-N 0.000 description 1
- LJOGYMKVIXXPLX-UHFFFAOYSA-N 2-[3-[4-[4-[(dimethylamino)methyl]oxan-4-yl]phenoxy]propyl-ethylamino]ethanol Chemical compound C1=CC(OCCCN(CCO)CC)=CC=C1C1(CN(C)C)CCOCC1 LJOGYMKVIXXPLX-UHFFFAOYSA-N 0.000 description 1
- BLJCVWYTXXWPQB-UHFFFAOYSA-N 2-[3-chloropropyl(ethyl)amino]ethanol Chemical compound OCCN(CC)CCCCl BLJCVWYTXXWPQB-UHFFFAOYSA-N 0.000 description 1
- DTIOMUWLCSNKFN-UHFFFAOYSA-N 2-[3-chloropropyl(methyl)amino]ethanol Chemical compound OCCN(C)CCCCl DTIOMUWLCSNKFN-UHFFFAOYSA-N 0.000 description 1
- JUEAERRXRWRTRX-UHFFFAOYSA-N 2-[3-chloropropyl(methyl)amino]ethanol;2-(methylamino)ethanol Chemical compound CNCCO.OCCN(C)CCCCl JUEAERRXRWRTRX-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- ZSZKAQCISWFDCQ-UHFFFAOYSA-N 2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC=C1S(Cl)(=O)=O ZSZKAQCISWFDCQ-UHFFFAOYSA-N 0.000 description 1
- ODNMFKMUVPWDHF-UHFFFAOYSA-N 2-fluoroethaneperoxoic acid Chemical compound OOC(=O)CF ODNMFKMUVPWDHF-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- KCLCMSXMBFKJOT-UHFFFAOYSA-N 3-[4-[4-[(dimethylamino)methyl]oxan-4-yl]phenoxy]-n-propan-2-ylpropan-1-amine Chemical compound C1=CC(OCCCNC(C)C)=CC=C1C1(CN(C)C)CCOCC1 KCLCMSXMBFKJOT-UHFFFAOYSA-N 0.000 description 1
- OOOLJFNJIVXCHV-UHFFFAOYSA-N 3-chloro-N,N-diethylpropan-1-amine N-ethylethanamine Chemical compound C(C)NCC.ClCCCN(CC)CC OOOLJFNJIVXCHV-UHFFFAOYSA-N 0.000 description 1
- WVUULNDRFBHTFG-UHFFFAOYSA-N 3-chloro-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCCl WVUULNDRFBHTFG-UHFFFAOYSA-N 0.000 description 1
- MGUSKVMIXPXOLC-UHFFFAOYSA-N 3-chloro-n-methyl-n-propan-2-ylpropan-1-amine Chemical compound CC(C)N(C)CCCCl MGUSKVMIXPXOLC-UHFFFAOYSA-N 0.000 description 1
- LRJGXRBBOBKTSQ-UHFFFAOYSA-N 3-cyano-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]benzenesulfonamide Chemical compound C=1C=CC(C#N)=CC=1S(=O)(=O)NCC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 LRJGXRBBOBKTSQ-UHFFFAOYSA-N 0.000 description 1
- BHNRGBRMCNHNQD-UHFFFAOYSA-N 3-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(C#N)=C1 BHNRGBRMCNHNQD-UHFFFAOYSA-N 0.000 description 1
- JEGMWWXJUXDNJN-UHFFFAOYSA-N 3-methylpiperidine Chemical compound CC1CCCNC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 1
- CLUWOWRTHNNBBU-UHFFFAOYSA-N 3-methylthiopropanal Chemical compound CSCCC=O CLUWOWRTHNNBBU-UHFFFAOYSA-N 0.000 description 1
- IDUAOXZXTLZYIS-UHFFFAOYSA-N 3-piperidin-1-ylbutan-1-ol Chemical compound OCCC(C)N1CCCCC1 IDUAOXZXTLZYIS-UHFFFAOYSA-N 0.000 description 1
- OABUKBBBSMNNPM-UHFFFAOYSA-N 4,4-difluoropiperidin-1-ium;chloride Chemical compound Cl.FC1(F)CCNCC1 OABUKBBBSMNNPM-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- SYOBOTSCMVRZPR-UHFFFAOYSA-N 4-(3-methoxyphenyl)oxane-4-carbonitrile Chemical compound COC1=CC=CC(C2(CCOCC2)C#N)=C1 SYOBOTSCMVRZPR-UHFFFAOYSA-N 0.000 description 1
- CFYXTBGENNOKCL-UHFFFAOYSA-N 4-(4-hydroxyphenyl)oxane-4-carbonitrile tribromoborane Chemical compound B(Br)(Br)Br.OC1=CC=C(C=C1)C1(CCOCC1)C#N CFYXTBGENNOKCL-UHFFFAOYSA-N 0.000 description 1
- BKIOUGMRRNVDBC-UHFFFAOYSA-N 4-(aminomethyl)-4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexan-1-ol Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN)CCC(O)CC1 BKIOUGMRRNVDBC-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- QKYGFPHYJHPMQV-UHFFFAOYSA-N 4-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]oxane-4-carbonitrile Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1C1(C#N)CCOCC1 QKYGFPHYJHPMQV-UHFFFAOYSA-N 0.000 description 1
- HRYSFDVGRQYADA-UHFFFAOYSA-N 4-[4-(1-cyclopentylpiperidin-4-yl)oxyphenyl]oxane-4-carbonitrile Chemical compound C=1C=C(OC2CCN(CC2)C2CCCC2)C=CC=1C1(C#N)CCOCC1 HRYSFDVGRQYADA-UHFFFAOYSA-N 0.000 description 1
- JCQFZLTWHNSWNJ-UHFFFAOYSA-N 4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxane-4-carbonitrile Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C#N)C=C1 JCQFZLTWHNSWNJ-UHFFFAOYSA-N 0.000 description 1
- AHZZLKPOEREZMI-UHFFFAOYSA-N 4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxane-4-carbonitrile 4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxane-4-carboxamide Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C(=O)N.C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C#N AHZZLKPOEREZMI-UHFFFAOYSA-N 0.000 description 1
- QUWBGQHPKUBLLP-UHFFFAOYSA-N 4-[4-(3-chloropropoxy)phenyl]oxane-4-carbonitrile Chemical compound C1=CC(OCCCCl)=CC=C1C1(C#N)CCOCC1 QUWBGQHPKUBLLP-UHFFFAOYSA-N 0.000 description 1
- AETXRCSPRQGYEU-UHFFFAOYSA-N 4-[4-[3-(1,1-dioxo-1,4-thiazinan-4-yl)propoxy]phenyl]oxane-4-carbonitrile Chemical compound C1CS(=O)(=O)CCN1CCCOC1=CC=C(C2(CCOCC2)C#N)C=C1 AETXRCSPRQGYEU-UHFFFAOYSA-N 0.000 description 1
- SDIOMXGWHNGFKC-UHFFFAOYSA-N 4-[4-[3-(2-methylpiperidin-1-yl)propoxy]phenyl]oxane-4-carbonitrile Chemical class CC1CCCCN1CCCOC1=CC=C(C2(CCOCC2)C#N)C=C1 SDIOMXGWHNGFKC-UHFFFAOYSA-N 0.000 description 1
- GRYBSLAGZUWGGW-UHFFFAOYSA-N 4-[4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl]oxane-4-carbonitrile Chemical class C1C(C)CCCN1CCCOC1=CC=C(C2(CCOCC2)C#N)C=C1 GRYBSLAGZUWGGW-UHFFFAOYSA-N 0.000 description 1
- JZOLVCSYFZCFLD-UHFFFAOYSA-N 4-[4-[3-(4,4-difluoropiperidin-1-yl)propoxy]phenyl]oxane-4-carbonitrile Chemical compound C1CC(F)(F)CCN1CCCOC1=CC=C(C2(CCOCC2)C#N)C=C1 JZOLVCSYFZCFLD-UHFFFAOYSA-N 0.000 description 1
- UENPRRPCVIMMDA-UHFFFAOYSA-N 4-[4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]oxane-4-carbonitrile Chemical class C1CN(C)CCN1CCCOC1=CC=C(C2(CCOCC2)C#N)C=C1 UENPRRPCVIMMDA-UHFFFAOYSA-N 0.000 description 1
- YHRQEMXILBWPSY-UHFFFAOYSA-N 4-[4-[3-(4-methylpiperidin-1-yl)propoxy]phenyl]oxane-4-carbonitrile Chemical class C1CC(C)CCN1CCCOC1=CC=C(C2(CCOCC2)C#N)C=C1 YHRQEMXILBWPSY-UHFFFAOYSA-N 0.000 description 1
- MVKSABCYNAJURP-UHFFFAOYSA-N 4-[4-[3-(azepan-1-yl)propoxy]phenyl]oxane-4-carbonitrile Chemical class C=1C=C(OCCCN2CCCCCC2)C=CC=1C1(C#N)CCOCC1 MVKSABCYNAJURP-UHFFFAOYSA-N 0.000 description 1
- KRNVVAHZLDSRDV-UHFFFAOYSA-N 4-[[4-[4-[(1-propan-2-ylazetidin-3-yl)methoxy]phenyl]oxan-4-yl]methoxy]pyridine Chemical compound C1N(C(C)C)CC1COC1=CC=C(C2(COC=3C=CN=CC=3)CCOCC2)C=C1 KRNVVAHZLDSRDV-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- DAFCQQFMRRYKJY-UHFFFAOYSA-N 4-hydroxy-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexane-1-carbonitrile Chemical compound C1CC(O)CCC1(C#N)C(C=C1)=CC=C1OCCCN1CCCC1 DAFCQQFMRRYKJY-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- SHIIWUKLJUSVHG-UHFFFAOYSA-N 4-pyrrolidin-1-ylbutan-2-ol Chemical compound CC(O)CCN1CCCC1 SHIIWUKLJUSVHG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVTLNWZNKRDAOI-DDWIOCJRSA-N BrCCCO.C[C@H]1N(CCC1)CCCO Chemical compound BrCCCO.C[C@H]1N(CCC1)CCCO BVTLNWZNKRDAOI-DDWIOCJRSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- PIBLYEHCZPBCHH-UHFFFAOYSA-N C(C)(=O)N1CCN(CC1)CC1(CCCCC1)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C1=CN=CO1 Chemical compound C(C)(=O)N1CCN(CC1)CC1(CCCCC1)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C1=CN=CO1 PIBLYEHCZPBCHH-UHFFFAOYSA-N 0.000 description 1
- VATFZNNJMMTEQL-UHFFFAOYSA-N C(C)(=O)N1CCN(CC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)COC1=CC=NC=C1 Chemical compound C(C)(=O)N1CCN(CC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)COC1=CC=NC=C1 VATFZNNJMMTEQL-UHFFFAOYSA-N 0.000 description 1
- WXJPVMLWTYRDDV-UHFFFAOYSA-N C(C)(C)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CO.N1CCOCC1 Chemical compound C(C)(C)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CO.N1CCOCC1 WXJPVMLWTYRDDV-UHFFFAOYSA-N 0.000 description 1
- LOGRTBCCEVEESK-UHFFFAOYSA-N C(C)(C)N1CCC(CC1)(C#N)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCCCC1)CN1CCNCC1 Chemical compound C(C)(C)N1CCC(CC1)(C#N)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCCCC1)CN1CCNCC1 LOGRTBCCEVEESK-UHFFFAOYSA-N 0.000 description 1
- VIQOFIVMVDYUJH-UHFFFAOYSA-N C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCN(CC1)C.CNCC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCOCC1 Chemical compound C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCN(CC1)C.CNCC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCOCC1 VIQOFIVMVDYUJH-UHFFFAOYSA-N 0.000 description 1
- DAJFMWRPSMHYSK-UHFFFAOYSA-N C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=C(N1)C.CN(C)CC1(CCOCC1)C1=CC=C(OCCCN(C)C)C=C1 Chemical compound C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=C(N1)C.CN(C)CC1(CCOCC1)C1=CC=C(OCCCN(C)C)C=C1 DAJFMWRPSMHYSK-UHFFFAOYSA-N 0.000 description 1
- SBHKJVJVZSLVGZ-UHFFFAOYSA-N C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=CN1.C(C)(C)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CN1CCOCC1 Chemical compound C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=CN1.C(C)(C)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CN1CCOCC1 SBHKJVJVZSLVGZ-UHFFFAOYSA-N 0.000 description 1
- FPLVQVXKLPGSKY-UHFFFAOYSA-N C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC=1C=NC=CC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCNCC1)C#N Chemical compound C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC=1C=NC=CC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCNCC1)C#N FPLVQVXKLPGSKY-UHFFFAOYSA-N 0.000 description 1
- RUNKKNXUJGAAEC-UHFFFAOYSA-N C(C)(C)NC.ClCCCN(C)C(C)C Chemical compound C(C)(C)NC.ClCCCN(C)C(C)C RUNKKNXUJGAAEC-UHFFFAOYSA-N 0.000 description 1
- MDDKFPYDRQEHDB-UHFFFAOYSA-N C(C)N(C(=O)C1(CCOCC1)C1=CC=C(C=C1)OC1CCN(CC1)C(C)C)C.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNC1=CN=NC=C1 Chemical compound C(C)N(C(=O)C1(CCOCC1)C1=CC=C(C=C1)OC1CCN(CC1)C(C)C)C.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNC1=CN=NC=C1 MDDKFPYDRQEHDB-UHFFFAOYSA-N 0.000 description 1
- FAQWCGLFBXCBNW-UHFFFAOYSA-N C(C)N(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.CNCC1(CCCCC1)C1=CC=C(C=C1)OCCCN1CCCC1 Chemical compound C(C)N(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.CNCC1(CCCCC1)C1=CC=C(C=C1)OCCCN1CCCC1 FAQWCGLFBXCBNW-UHFFFAOYSA-N 0.000 description 1
- QYXFTWLDMAGWKT-UHFFFAOYSA-N C(C)N1CCN(CC1)C(=O)C1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.C1(CCC1)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CN Chemical compound C(C)N1CCN(CC1)C(=O)C1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.C1(CCC1)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CN QYXFTWLDMAGWKT-UHFFFAOYSA-N 0.000 description 1
- IHRKRYYSQZSRPE-UHFFFAOYSA-N C(C)NCCO.ClCCCN(CCO)CC Chemical compound C(C)NCCO.ClCCCN(CCO)CC IHRKRYYSQZSRPE-UHFFFAOYSA-N 0.000 description 1
- RYYJOQOYXDAAGM-UHFFFAOYSA-N C(C)OC(=O)N1CCNCC1.C(C)OC(=O)N1CCN(CC1)CCCCl Chemical compound C(C)OC(=O)N1CCNCC1.C(C)OC(=O)N1CCN(CC1)CCCCl RYYJOQOYXDAAGM-UHFFFAOYSA-N 0.000 description 1
- BEYFMPXKISQQBI-FUKRVRFJSA-N C(C1=CC=CC=C1)N1C[C@@H](CC1)OC.C(C1=CC=CC=C1)N1C[C@@H](CC1)OC Chemical compound C(C1=CC=CC=C1)N1C[C@@H](CC1)OC.C(C1=CC=CC=C1)N1C[C@@H](CC1)OC BEYFMPXKISQQBI-FUKRVRFJSA-N 0.000 description 1
- OAXMEUNYIMHIHG-UHFFFAOYSA-N C(CC)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C#N.C(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C#N Chemical compound C(CC)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C#N.C(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C#N OAXMEUNYIMHIHG-UHFFFAOYSA-N 0.000 description 1
- UQUOUPAWRBBMFG-UHFFFAOYSA-N C1(CCC1)N(CCCC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1)C Chemical compound C1(CCC1)N(CCCC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1)C UQUOUPAWRBBMFG-UHFFFAOYSA-N 0.000 description 1
- NXODBUZIAZWHDY-UHFFFAOYSA-N C1(CCC1)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1.N1(CCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCCC2)C=C1 Chemical compound C1(CCC1)N1CC(C1)COC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1.N1(CCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCCC2)C=C1 NXODBUZIAZWHDY-UHFFFAOYSA-N 0.000 description 1
- DQSNXKDKGIMVAG-UHFFFAOYSA-N C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCOCC1.C(C)N1CCN(CC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1 Chemical compound C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCOCC1.C(C)N1CCN(CC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1 DQSNXKDKGIMVAG-UHFFFAOYSA-N 0.000 description 1
- VAPLRDSHOMCJQF-UHFFFAOYSA-N C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=C(N1)C.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)NC Chemical compound C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=C(N1)C.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)NC VAPLRDSHOMCJQF-UHFFFAOYSA-N 0.000 description 1
- ZVJCYLAZZZDWSQ-UHFFFAOYSA-N C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CN(C)C.N1(CCSCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNCC Chemical compound C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CN(C)C.N1(CCSCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNCC ZVJCYLAZZZDWSQ-UHFFFAOYSA-N 0.000 description 1
- UAUKIFKXNHESGI-UHFFFAOYSA-N C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=CN1 Chemical compound C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C=1SC=CN1 UAUKIFKXNHESGI-UHFFFAOYSA-N 0.000 description 1
- ZZKZFBGWXUYNRN-UHFFFAOYSA-N C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=N1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)NCC Chemical compound C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=N1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)NCC ZZKZFBGWXUYNRN-UHFFFAOYSA-N 0.000 description 1
- DIYFQBVBDLYFHX-UHFFFAOYSA-N CN(C)CC1(CCOCC1)C1=CC=C(OCCCN2CC(CC2)O)C=C1.CN(CC1(CCOCC1)C1=CC=C(C=C1)SCCN1CCCC1)C Chemical compound CN(C)CC1(CCOCC1)C1=CC=C(OCCCN2CC(CC2)O)C=C1.CN(CC1(CCOCC1)C1=CC=C(C=C1)SCCN1CCCC1)C DIYFQBVBDLYFHX-UHFFFAOYSA-N 0.000 description 1
- UZXRFYDOXUAYBJ-UHFFFAOYSA-N CN(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNCC Chemical compound CN(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNCC UZXRFYDOXUAYBJ-UHFFFAOYSA-N 0.000 description 1
- ANFHWKRSDWRPCS-UHFFFAOYSA-N CN(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCSCC1.C(C)(=O)N Chemical compound CN(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCSCC1.C(C)(=O)N ANFHWKRSDWRPCS-UHFFFAOYSA-N 0.000 description 1
- YPDGNBKTXGDGQW-UHFFFAOYSA-N CN(CC1=NC=CC=C1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.O1CCC(CC1)C(=O)N Chemical compound CN(CC1=NC=CC=C1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.O1CCC(CC1)C(=O)N YPDGNBKTXGDGQW-UHFFFAOYSA-N 0.000 description 1
- RLHLRFLHGRCXSY-UHFFFAOYSA-N CN1CCN(CC1)C(=O)C1(CCCCC1)C1=CC=C(C=C1)OCCCN1CCCC1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC=1C=NC=CC1 Chemical compound CN1CCN(CC1)C(=O)C1(CCCCC1)C1=CC=C(C=C1)OCCCN1CCCC1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)CNC=1C=NC=CC1 RLHLRFLHGRCXSY-UHFFFAOYSA-N 0.000 description 1
- AFTYZCAINYZHGJ-UHFFFAOYSA-N CN1CCN(CC1)C(=O)C1(CCCCC1)C1=CC=C(OCCCN2CCOCC2)C=C1.C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)COC1=CC=NC=C1 Chemical compound CN1CCN(CC1)C(=O)C1(CCCCC1)C1=CC=C(OCCCN2CCOCC2)C=C1.C(C)(C)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)COC1=CC=NC=C1 AFTYZCAINYZHGJ-UHFFFAOYSA-N 0.000 description 1
- RNBYJCMYWLBFQA-UHFFFAOYSA-N CN1CCN(CCC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)NC(C)C Chemical compound CN1CCN(CCC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1.C1(CCC1)N1CCC(CC1)OC1=CC=C(C=C1)C1(CCOCC1)C(=O)NC(C)C RNBYJCMYWLBFQA-UHFFFAOYSA-N 0.000 description 1
- JQICJWTUKLWCQV-UHFFFAOYSA-N CO.O1CCC(CC1)C(=O)O Chemical compound CO.O1CCC(CC1)C(=O)O JQICJWTUKLWCQV-UHFFFAOYSA-N 0.000 description 1
- CHBVEXKQNQSKDK-UHFFFAOYSA-N COC1CCNCC1.ClCCCN1CCC(CC1)OC Chemical compound COC1CCNCC1.ClCCCN1CCC(CC1)OC CHBVEXKQNQSKDK-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 208000025985 Central nervous system inflammatory disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- MAVYIHRQAKMRDO-UHFFFAOYSA-N N-[[4-[4-(3-pyrrolidin-1-ylpropylsulfanyl)phenyl]oxan-4-yl]methyl]acetamide N-[[4-[4-(3-pyrrolidin-1-ylpropylsulfanyl)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound CCNCC1(CCOCC1)c1ccc(SCCCN2CCCC2)cc1.CC(=O)NCC1(CCOCC1)c1ccc(SCCCN2CCCC2)cc1 MAVYIHRQAKMRDO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZIDPNBFHYQGNNJ-UHFFFAOYSA-N N1(C=NC=C1)CC1(CCOCC1)C1=CC=C(OC2CCN(CC2)C(C)C)C=C1.N1CCOCC1 Chemical compound N1(C=NC=C1)CC1(CCOCC1)C1=CC=C(OC2CCN(CC2)C(C)C)C=C1.N1CCOCC1 ZIDPNBFHYQGNNJ-UHFFFAOYSA-N 0.000 description 1
- IAIXNCODMWWOOP-UHFFFAOYSA-N N1(CC1)CC1(CCOCC1)C1=CC=C(OCCCN2CCCC2)C=C1.C1(CC1)N Chemical compound N1(CC1)CC1(CCOCC1)C1=CC=C(OCCCN2CCCC2)C=C1.C1(CC1)N IAIXNCODMWWOOP-UHFFFAOYSA-N 0.000 description 1
- WVQHHURJCBDXJS-UHFFFAOYSA-N N1(CCCC1)C(=O)C1(CCOCC1)C1=CC=C(C=C1)SCCCN1CCCCC1.N1(CCCC1)CCCSC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCCCC1 Chemical compound N1(CCCC1)C(=O)C1(CCOCC1)C1=CC=C(C=C1)SCCCN1CCCCC1.N1(CCCC1)CCCSC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCCCC1 WVQHHURJCBDXJS-UHFFFAOYSA-N 0.000 description 1
- QHYMWJDXVBEIQM-UHFFFAOYSA-N N1(CCCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCCC2)C=C1.CN1CCC(CC1)(C#N)C1=CC=C(C=C1)OCCCN1CCCC1 Chemical compound N1(CCCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCCC2)C=C1.CN1CCC(CC1)(C#N)C1=CC=C(C=C1)OCCCN1CCCC1 QHYMWJDXVBEIQM-UHFFFAOYSA-N 0.000 description 1
- AGWSXYNJZDISRZ-UHFFFAOYSA-N N1(CCCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCSCC2)C=C1.C(C)N(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCSCC1 Chemical compound N1(CCCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCSCC2)C=C1.C(C)N(CC)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCSCC1 AGWSXYNJZDISRZ-UHFFFAOYSA-N 0.000 description 1
- JVLFINMWRLWWSF-UHFFFAOYSA-N N1(CCCC1)CCCCOC1=CC=C(C=C1)C1(CCOCC1)C=1SC=CN1.CC=1N=C(SC1)C1(CCOCC1)C1=CC=C(C=C1)OCCCCN1CCCC1 Chemical compound N1(CCCC1)CCCCOC1=CC=C(C=C1)C1(CCOCC1)C=1SC=CN1.CC=1N=C(SC1)C1(CCOCC1)C1=CC=C(C=C1)OCCCCN1CCCC1 JVLFINMWRLWWSF-UHFFFAOYSA-N 0.000 description 1
- PPGRSXULDIHNRF-UHFFFAOYSA-N N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCCCC1)CN1CCC(CC1)O.N1(CCCC1)CC1(CCOCC1)C1=CC=C(C=C1)SCCCN1CCCC1 Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCCCC1)CN1CCC(CC1)O.N1(CCCC1)CC1(CCOCC1)C1=CC=C(C=C1)SCCCN1CCCC1 PPGRSXULDIHNRF-UHFFFAOYSA-N 0.000 description 1
- JVUHZHXRCYLDDJ-UHFFFAOYSA-N N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCCCC1.N1(CCOCC1)CC1(CCOCC1)C1=CC=C(OCCCN2CCOCCC2)C=C1 Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C(=O)N1CCCCC1.N1(CCOCC1)CC1(CCOCC1)C1=CC=C(OCCCN2CCOCCC2)C=C1 JVUHZHXRCYLDDJ-UHFFFAOYSA-N 0.000 description 1
- IFGLKFSOPIQWKN-UHFFFAOYSA-N N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C1=NC=CC=C1.COCCN1NC=C(C=C1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1 Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C1=NC=CC=C1.COCCN1NC=C(C=C1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1 IFGLKFSOPIQWKN-UHFFFAOYSA-N 0.000 description 1
- SPZDTPVJYSCDIA-UHFFFAOYSA-N N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C1=NC=NC=C1.CN1CCN(CC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCOCCC2)C=C1 Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C1=NC=NC=C1.CN1CCN(CC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCOCCC2)C=C1 SPZDTPVJYSCDIA-UHFFFAOYSA-N 0.000 description 1
- QHYIDARWIYMZSJ-UHFFFAOYSA-N N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C=1NC=CN1.N1(CCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1CCOCC1 Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C=1NC=CN1.N1(CCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1CCOCC1 QHYIDARWIYMZSJ-UHFFFAOYSA-N 0.000 description 1
- KXCDUVGKCXTDOP-UHFFFAOYSA-N N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1.C(CC)N1CCN(CC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1 Chemical compound N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNC1=NC=CC=C1.C(CC)N1CCN(CC1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1 KXCDUVGKCXTDOP-UHFFFAOYSA-N 0.000 description 1
- ZWHRXZOLFVPVCN-UHFFFAOYSA-N N1(CCNCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCOCC2)C=C1.CN1CCN(CC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCOCC2)C=C1 Chemical compound N1(CCNCC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCOCC2)C=C1.CN1CCN(CC1)C(=O)C1(CCOCC1)C1=CC=C(OCCCN2CCOCC2)C=C1 ZWHRXZOLFVPVCN-UHFFFAOYSA-N 0.000 description 1
- QRLMDBRASZFMQZ-UHFFFAOYSA-N N1(CCOCC1)CC1(CCOCC1)C1=CC=C(OCCCN2CCOCC2)C=C1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNC=1C=NC=CC1 Chemical compound N1(CCOCC1)CC1(CCOCC1)C1=CC=C(OCCCN2CCOCC2)C=C1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CNC=1C=NC=CC1 QRLMDBRASZFMQZ-UHFFFAOYSA-N 0.000 description 1
- IHDWABMSLXRTCC-UHFFFAOYSA-N N1(CCSCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1CC=CC=C1.C(C)N(CC)CC1(CCOCC1)C1=CC=C(C=C1)SCCCN1CCCC1 Chemical compound N1(CCSCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1CC=CC=C1.C(C)N(CC)CC1(CCOCC1)C1=CC=C(C=C1)SCCCN1CCCC1 IHDWABMSLXRTCC-UHFFFAOYSA-N 0.000 description 1
- QFKQXUVPPYBRQN-UHFFFAOYSA-N N1CCC(CC1)CCO.ClCCCN1CCC(CC1)CCO Chemical compound N1CCC(CC1)CCO.ClCCCN1CCC(CC1)CCO QFKQXUVPPYBRQN-UHFFFAOYSA-N 0.000 description 1
- DXXDBPNZFOZSLW-UHFFFAOYSA-N N1CCSCC1.ClCCCN1CCSCC1 Chemical compound N1CCSCC1.ClCCCN1CCSCC1 DXXDBPNZFOZSLW-UHFFFAOYSA-N 0.000 description 1
- ADLIIVHZEBLGOR-UHFFFAOYSA-N NCC1(CCOCC1)C1=CC=C(OCCCNC2CCC2)C=C1.CN(C1CN(C1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1)C Chemical compound NCC1(CCOCC1)C1=CC=C(OCCCNC2CCC2)C=C1.CN(C1CN(C1)CC1(CCOCC1)C1=CC=C(C=C1)OCCCN1CCCC1)C ADLIIVHZEBLGOR-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GLEYDBVADKWICS-UHFFFAOYSA-N O1CCC(CC1)C(=O)NC1=CC=C(C=C1)OC1CCN(CC1)C1CCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1C=NC2=C1C=CC=C2 Chemical compound O1CCC(CC1)C(=O)NC1=CC=C(C=C1)OC1CCN(CC1)C1CCC1.N1(CCCC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)CN1C=NC2=C1C=CC=C2 GLEYDBVADKWICS-UHFFFAOYSA-N 0.000 description 1
- JQNIDGWWUDCGHX-UHFFFAOYSA-N O1CCC(CC1)C(=O)NC1=CC=C(C=C1)OCCCCN1CCCC1.C(C)N(CCCOC1=CC=C(C=C1)C1(CCOCC1)C#N)C Chemical compound O1CCC(CC1)C(=O)NC1=CC=C(C=C1)OCCCCN1CCCC1.C(C)N(CCCOC1=CC=C(C=C1)C1(CCOCC1)C#N)C JQNIDGWWUDCGHX-UHFFFAOYSA-N 0.000 description 1
- RNFADMZTCLPORR-UHFFFAOYSA-N OC1=CC=C(C=C1)C1(CCOCC1)C#N.BrCCCOC1=CC=C(C=C1)C1(CCOCC1)C#N Chemical compound OC1=CC=C(C=C1)C1(CCOCC1)C#N.BrCCCOC1=CC=C(C=C1)C1(CCOCC1)C#N RNFADMZTCLPORR-UHFFFAOYSA-N 0.000 description 1
- FRQLKJNSPSPLNE-HRWXGAKPSA-N O[C@H]1CN(CC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C#N.CC(CCN1CCCC1)OC1=CC=C(C=C1)C1(CCOCC1)C#N Chemical compound O[C@H]1CN(CC1)CCCOC1=CC=C(C=C1)C1(CCOCC1)C#N.CC(CCN1CCCC1)OC1=CC=C(C=C1)C1(CCOCC1)C#N FRQLKJNSPSPLNE-HRWXGAKPSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000006778 Pummerer Sulfoxide rearrangement reaction Methods 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- KWUUUJOYSZASFM-UHFFFAOYSA-N [1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexyl]methanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN)CCCCC1 KWUUUJOYSZASFM-UHFFFAOYSA-N 0.000 description 1
- BEDMFKWZZULEJX-HXUWFJFHSA-N [1-[4-[3-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]propoxy]phenyl]cyclohexyl]methanamine Chemical compound COC[C@H]1CCCN1CCCOC1=CC=C(C2(CN)CCCCC2)C=C1 BEDMFKWZZULEJX-HXUWFJFHSA-N 0.000 description 1
- UFXQGLZXMWYWEC-FQEVSTJZSA-N [1-[4-[3-[(3s)-3-methoxypyrrolidin-1-yl]propoxy]phenyl]cyclohexyl]methanamine Chemical compound C1[C@@H](OC)CCN1CCCOC1=CC=C(C2(CN)CCCCC2)C=C1 UFXQGLZXMWYWEC-FQEVSTJZSA-N 0.000 description 1
- IZDDFPAHBCLTTP-UHFFFAOYSA-N [3-(dimethylamino)azetidin-1-yl]-[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanone Chemical compound C1C(N(C)C)CN1C(=O)C1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 IZDDFPAHBCLTTP-UHFFFAOYSA-N 0.000 description 1
- CICNVPXSEFWGBP-UHFFFAOYSA-N [4-(4-methoxyphenyl)oxan-4-yl]methanamine Chemical compound C1=CC(OC)=CC=C1C1(CN)CCOCC1 CICNVPXSEFWGBP-UHFFFAOYSA-N 0.000 description 1
- MSHQIBJUQKNMKP-UHFFFAOYSA-N [4-[4-(3-pyrrolidin-1-ylpropylsulfanyl)phenyl]oxan-4-yl]methanol Chemical compound C=1C=C(SCCCN2CCCC2)C=CC=1C1(CO)CCOCC1 MSHQIBJUQKNMKP-UHFFFAOYSA-N 0.000 description 1
- TZSUVHAONGAZON-JOCHJYFZSA-N [4-[4-[3-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]oxan-4-yl]-morpholin-4-ylmethanone Chemical compound C1[C@H](N(C)C)CCN1CCCOC1=CC=C(C2(CCOCC2)C(=O)N2CCOCC2)C=C1 TZSUVHAONGAZON-JOCHJYFZSA-N 0.000 description 1
- LVZGQWKTUCVPBQ-UHFFFAOYSA-N acetic acid;trifluoroborane Chemical compound CC(O)=O.FB(F)F LVZGQWKTUCVPBQ-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000002163 alpha 1-adrenoceptor agonist Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004012 amifampridine Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- IGOQJWBTUFQTGN-UHFFFAOYSA-N azetidin-1-yl-[4-[4-(4-pyrrolidin-1-ylbutoxy)phenyl]oxan-4-yl]methanone Chemical compound C1COCCC1(C=1C=CC(OCCCCN2CCCC2)=CC=1)C(=O)N1CCC1 IGOQJWBTUFQTGN-UHFFFAOYSA-N 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- IRDLUHRVLVEUHA-UHFFFAOYSA-N diethyl dithiophosphate Chemical compound CCOP(S)(=S)OCC IRDLUHRVLVEUHA-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- FPGYTTSMRFMJOF-UHFFFAOYSA-N ethyl 4-(3-chloropropyl)piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(CCCCl)CC1 FPGYTTSMRFMJOF-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- UVYKKFKLOUEFAR-UHFFFAOYSA-N hydron;piperazine-1-carboxamide;chloride Chemical compound Cl.NC(=O)N1CCNCC1 UVYKKFKLOUEFAR-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- PHFWPZLMPBRBFM-UHFFFAOYSA-N methyl 4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxane-4-carboxylate Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(C(=O)OC)CCOCC1 PHFWPZLMPBRBFM-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- KTWUOXKFUJTMAS-UHFFFAOYSA-N morpholin-4-yl-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methanone Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C(=O)N2CCOCC2)C=C1 KTWUOXKFUJTMAS-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- JCODJTDKFILNIN-UHFFFAOYSA-N n,n,n'-trimethyl-n'-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]ethane-1,2-diamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)CCN(C)C)CCOCC1 JCODJTDKFILNIN-UHFFFAOYSA-N 0.000 description 1
- RURMGFDXSCKGBS-UHFFFAOYSA-N n,n-diethyl-4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxane-4-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C=CC=1C1(C(=O)N(CC)CC)CCOCC1 RURMGFDXSCKGBS-UHFFFAOYSA-N 0.000 description 1
- PQSOLLURQXDZSZ-UHFFFAOYSA-N n,n-diethylethanamine;ethyl acetate;methanol Chemical compound OC.CCOC(C)=O.CCN(CC)CC PQSOLLURQXDZSZ-UHFFFAOYSA-N 0.000 description 1
- QXJSQMRKHLAENO-UHFFFAOYSA-N n,n-dimethyl-1-[4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=CC(OCCCN2CCCC2)=CC=1C1(CN(C)C)CCOCC1 QXJSQMRKHLAENO-UHFFFAOYSA-N 0.000 description 1
- XOTCZJPOHPSCRO-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(3-pyrrolidin-1-ylpropylsulfanyl)phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(SCCCN2CCCC2)C=CC=1C1(CN(C)C)CCOCC1 XOTCZJPOHPSCRO-UHFFFAOYSA-N 0.000 description 1
- GGMIPCBWWMFXKM-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-[3-(1,4-oxazepan-4-yl)propoxy]phenyl]oxan-4-yl]methanamine Chemical compound C=1C=C(OCCCN2CCOCCC2)C=CC=1C1(CN(C)C)CCOCC1 GGMIPCBWWMFXKM-UHFFFAOYSA-N 0.000 description 1
- IBTLOSXTRODYDW-LJQANCHMSA-N n,n-dimethyl-1-[4-[4-[3-[(3r)-3-methylmorpholin-4-yl]propoxy]phenyl]oxan-4-yl]methanamine Chemical compound C[C@@H]1COCCN1CCCOC1=CC=C(C2(CN(C)C)CCOCC2)C=C1 IBTLOSXTRODYDW-LJQANCHMSA-N 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- PUVWLUZKWDASFY-UHFFFAOYSA-N n-[[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methyl]pyrimidin-2-amine Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CNC=3N=CC=CN=3)CCOCC2)C=C1 PUVWLUZKWDASFY-UHFFFAOYSA-N 0.000 description 1
- CDJKKZQFBHWYBO-UHFFFAOYSA-N n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]pyrimidin-2-amine Chemical compound C1CCCN1CCCOC(C=C1)=CC=C1C1(CNC=2N=CC=CN=2)CCOCC1 CDJKKZQFBHWYBO-UHFFFAOYSA-N 0.000 description 1
- NKJDSJQYBKSGLC-OAQYLSRUSA-N n-[[4-[4-[3-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]oxan-4-yl]methyl]-n-methylmethanesulfonamide Chemical compound C1[C@H](N(C)C)CCN1CCCOC1=CC=C(C2(CN(C)S(C)(=O)=O)CCOCC2)C=C1 NKJDSJQYBKSGLC-OAQYLSRUSA-N 0.000 description 1
- AHPNTQSXUIJIQH-HSZRJFAPSA-N n-[[4-[4-[3-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]oxan-4-yl]methyl]-n-methylpyrimidin-2-amine Chemical compound C1[C@H](N(C)C)CCN1CCCOC1=CC=C(C2(CN(C)C=3N=CC=CN=3)CCOCC2)C=C1 AHPNTQSXUIJIQH-HSZRJFAPSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UMFGUOZDPSWIHT-UHFFFAOYSA-N n-methyl-1-[1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]cyclohexyl]methanamine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CNC)CCCCC1 UMFGUOZDPSWIHT-UHFFFAOYSA-N 0.000 description 1
- NSAIGWVABDICEO-UHFFFAOYSA-N n-methyl-4-[4-(3-piperidin-1-ylpropoxy)phenyl]oxan-4-amine Chemical compound C=1C=C(OCCCN2CCCCC2)C=CC=1C1(NC)CCOCC1 NSAIGWVABDICEO-UHFFFAOYSA-N 0.000 description 1
- DUJWSLPKNTXMIW-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]cyclohexanamine Chemical compound C1CCCCC1N(C)CC1(C=2C=CC(OCCCN3CCCC3)=CC=2)CCOCC1 DUJWSLPKNTXMIW-UHFFFAOYSA-N 0.000 description 1
- ZIELLCUUKRXXPV-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]oxan-4-yl]methyl]hexan-1-amine Chemical compound C=1C=C(OCCCN2CCCC2)C=CC=1C1(CN(C)CCCCCC)CCOCC1 ZIELLCUUKRXXPV-UHFFFAOYSA-N 0.000 description 1
- AVQJGGCZWMVOQB-UHFFFAOYSA-N n-methyl-n-[[4-[4-(3-pyrrolidin-1-ylpropylsulfanyl)phenyl]oxan-4-yl]methyl]ethanamine Chemical compound C=1C=C(SCCCN2CCCC2)C=CC=1C1(CN(C)CC)CCOCC1 AVQJGGCZWMVOQB-UHFFFAOYSA-N 0.000 description 1
- KYKUNUSOJLUNJZ-UHFFFAOYSA-N n-methyl-n-propan-2-yl-4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxane-4-carboxamide Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C=CC=1C1(C(=O)N(C)C(C)C)CCOCC1 KYKUNUSOJLUNJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- CXLGNJCMPWUZKM-UHFFFAOYSA-N oxane-4-carbaldehyde Chemical compound O=CC1CCOCC1 CXLGNJCMPWUZKM-UHFFFAOYSA-N 0.000 description 1
- RLZJFTOYCVIYLE-UHFFFAOYSA-N oxane-4-carbonitrile Chemical class N#CC1CCOCC1 RLZJFTOYCVIYLE-UHFFFAOYSA-N 0.000 description 1
- AVPKHOTUOHDTLW-UHFFFAOYSA-N oxane-4-carboxylic acid Chemical compound OC(=O)C1CCOCC1 AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OWJOYGAWHXFLFX-UHFFFAOYSA-N piperidin-1-yl-[4-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]oxan-4-yl]methanone Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(C2(CCOCC2)C(=O)N2CCCCC2)C=C1 OWJOYGAWHXFLFX-UHFFFAOYSA-N 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- GZOJHHKWMFNXAB-UHFFFAOYSA-N pyrrolidin-1-yl-[4-[4-(4-pyrrolidin-1-ylbutoxy)phenyl]oxan-4-yl]methanone Chemical compound C1COCCC1(C=1C=CC(OCCCCN2CCCC2)=CC=1)C(=O)N1CCCC1 GZOJHHKWMFNXAB-UHFFFAOYSA-N 0.000 description 1
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012418 sodium perborate tetrahydrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- NGIGLOKJPWGIJT-QMMMGPOBSA-N tert-butyl (3s)-3-methoxypyrrolidine-1-carboxylate Chemical compound CO[C@H]1CCN(C(=O)OC(C)(C)C)C1 NGIGLOKJPWGIJT-QMMMGPOBSA-N 0.000 description 1
- YRYNLXXXMXAVKV-UHFFFAOYSA-N tert-butyl 4-(3-chloropropyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCCCl)CC1 YRYNLXXXMXAVKV-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04291187A EP1593679A1 (en) | 2004-05-07 | 2004-05-07 | 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands |
GB0504564A GB0504564D0 (en) | 2005-03-04 | 2005-03-04 | New compounds |
PCT/IB2005/001114 WO2005108384A1 (en) | 2004-05-07 | 2005-04-19 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007276853A Division JP2008050365A (ja) | 2004-05-07 | 2007-10-24 | H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007536365A JP2007536365A (ja) | 2007-12-13 |
JP4173191B2 true JP4173191B2 (ja) | 2008-10-29 |
Family
ID=34964551
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007512541A Expired - Fee Related JP4173191B2 (ja) | 2004-05-07 | 2005-04-19 | H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 |
JP2007276853A Withdrawn JP2008050365A (ja) | 2004-05-07 | 2007-10-24 | H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007276853A Withdrawn JP2008050365A (ja) | 2004-05-07 | 2007-10-24 | H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP1747210B1 (xx) |
JP (2) | JP4173191B2 (xx) |
KR (1) | KR100843848B1 (xx) |
CN (1) | CN1950351B (xx) |
AP (1) | AP2353A (xx) |
AR (1) | AR048939A1 (xx) |
AT (1) | ATE472540T1 (xx) |
AU (1) | AU2005240846B2 (xx) |
BR (1) | BRPI0510664B8 (xx) |
CA (1) | CA2565852C (xx) |
CR (1) | CR8729A (xx) |
CY (1) | CY1110735T1 (xx) |
DE (1) | DE602005022062D1 (xx) |
DK (1) | DK1747210T3 (xx) |
EA (1) | EA011161B1 (xx) |
EC (1) | ECSP066975A (xx) |
ES (1) | ES2346665T3 (xx) |
GE (1) | GEP20094826B (xx) |
GT (1) | GT200500107A (xx) |
HK (1) | HK1100823A1 (xx) |
HR (1) | HRP20100469T1 (xx) |
IL (1) | IL178433A (xx) |
MA (1) | MA28634B1 (xx) |
MX (1) | MXPA06012819A (xx) |
MY (1) | MY144634A (xx) |
NL (1) | NL1028968C2 (xx) |
NZ (1) | NZ550769A (xx) |
PA (1) | PA8632201A1 (xx) |
PE (1) | PE20060237A1 (xx) |
PL (1) | PL1747210T3 (xx) |
PT (1) | PT1747210E (xx) |
RS (1) | RS51403B (xx) |
SI (1) | SI1747210T1 (xx) |
SV (1) | SV2006002107A (xx) |
TW (2) | TWI346549B (xx) |
UY (1) | UY28883A1 (xx) |
WO (1) | WO2005108384A1 (xx) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
JP2007517056A (ja) | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールdaao阻害剤 |
JP2006213674A (ja) * | 2005-02-07 | 2006-08-17 | Ube Ind Ltd | 4−ホルミルテトラヒドロピラン化合物の製法 |
JP2009500425A (ja) | 2005-07-06 | 2009-01-08 | セプラコア インコーポレーテッド | エスゾピクロン及びトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−n−メチル−1−ナフタレンアミン又はトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−1−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 |
WO2007045989A1 (en) * | 2005-10-20 | 2007-04-26 | Pfizer Limited | Pyridyl derivatives useful as h3 ligands |
RU2430913C2 (ru) | 2006-01-06 | 2011-10-10 | Сепракор Инк. | Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина |
JP5438975B2 (ja) | 2006-01-06 | 2014-03-12 | サノビオン ファーマシューティカルズ インク | テトラロン系モノアミン再取り込み阻害剤 |
DK2013835T3 (en) | 2006-03-31 | 2015-12-14 | Sunovion Pharmaceuticals Inc | Preparation of chiral amides and AMINES |
MX2008013137A (es) | 2006-04-11 | 2008-10-21 | Novartis Ag | Compuestos organicos. |
EP2049472B1 (en) * | 2006-06-23 | 2015-01-21 | AbbVie Bahamas Ltd. | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
WO2008077597A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
SG186885A1 (en) | 2010-06-04 | 2013-02-28 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
CN103906746B (zh) * | 2011-10-26 | 2015-12-09 | 辉瑞有限公司 | 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 |
WO2014095534A1 (en) * | 2012-12-19 | 2014-06-26 | Basf Se | New substituted triazoles and imidazoles and their use as fungicides |
ES2647965T3 (es) * | 2013-01-09 | 2017-12-27 | Arena Pharmaceuticals, Inc. | Derivados de bifenil-etil-pirrolidina como moduladores del receptor de histamina H3 para el tratamiento de trastornos cognitivos |
TWI731317B (zh) * | 2013-12-10 | 2021-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶(trk)抑制劑 |
KR102561692B1 (ko) | 2014-12-18 | 2023-07-28 | 젠자임 코포레이션 | 트로포미오신-관련 키나제(trk) 억제제의 약제학적 제형 |
CN113336715B (zh) * | 2021-08-04 | 2021-11-23 | 山东海利尔化工有限公司 | 一种含二氧戊环的三唑类化合物及其中间体的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3024836A1 (de) * | 1980-07-01 | 1982-01-28 | A. Nattermann & Cie GmbH, 5000 Köln | (3-alkylamino-2-hydroxy-propoxy)-benzylnitrile, verfahren zu deren herstellung und diese als wirkstof enthaltende arzneimittel |
DK368687A (da) * | 1986-11-21 | 1988-05-22 | Cheminova As | Aminoalkylerede hydroxyforbindelser og deres anvendelse som fungicider |
JP4516717B2 (ja) * | 2000-07-13 | 2010-08-04 | アボット・ラボラトリーズ | ヒスタミン−3受容体リガンドとしての1,3−二置換ピロリジン及び1,3,3−三置換ピロリジン並びにそれらの治療的応用 |
DK1311482T3 (da) * | 2000-08-08 | 2007-05-07 | Ortho Mcneil Pharm Inc | Ikke-imidazolaryloxypiperidiner som H3-receptorligander |
EP1379493A2 (en) * | 2001-03-23 | 2004-01-14 | Eli Lilly and Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
-
2005
- 2005-04-19 DE DE602005022062T patent/DE602005022062D1/de active Active
- 2005-04-19 CN CN2005800146623A patent/CN1950351B/zh not_active Expired - Fee Related
- 2005-04-19 EA EA200601868A patent/EA011161B1/ru not_active IP Right Cessation
- 2005-04-19 SI SI200531085T patent/SI1747210T1/sl unknown
- 2005-04-19 KR KR1020067023284A patent/KR100843848B1/ko not_active IP Right Cessation
- 2005-04-19 PL PL05718521T patent/PL1747210T3/pl unknown
- 2005-04-19 BR BRPI0510664A patent/BRPI0510664B8/pt active IP Right Grant
- 2005-04-19 WO PCT/IB2005/001114 patent/WO2005108384A1/en active Application Filing
- 2005-04-19 PT PT05718521T patent/PT1747210E/pt unknown
- 2005-04-19 NZ NZ550769A patent/NZ550769A/en not_active IP Right Cessation
- 2005-04-19 AU AU2005240846A patent/AU2005240846B2/en not_active Ceased
- 2005-04-19 MX MXPA06012819A patent/MXPA06012819A/es not_active Application Discontinuation
- 2005-04-19 ES ES05718521T patent/ES2346665T3/es active Active
- 2005-04-19 GE GEAP20059693A patent/GEP20094826B/en unknown
- 2005-04-19 RS RSP-2010/0382A patent/RS51403B/en unknown
- 2005-04-19 CA CA2565852A patent/CA2565852C/en not_active Expired - Fee Related
- 2005-04-19 AP AP2006003772A patent/AP2353A/xx active
- 2005-04-19 JP JP2007512541A patent/JP4173191B2/ja not_active Expired - Fee Related
- 2005-04-19 EP EP05718521A patent/EP1747210B1/en active Active
- 2005-04-19 AT AT05718521T patent/ATE472540T1/de active
- 2005-04-19 DK DK05718521.7T patent/DK1747210T3/da active
- 2005-05-04 NL NL1028968A patent/NL1028968C2/nl not_active IP Right Cessation
- 2005-05-04 PE PE2005000505A patent/PE20060237A1/es not_active Application Discontinuation
- 2005-05-04 UY UY28883A patent/UY28883A1/es unknown
- 2005-05-05 GT GT200500107A patent/GT200500107A/es unknown
- 2005-05-05 MY MYPI20052001A patent/MY144634A/en unknown
- 2005-05-05 AR ARP050101824A patent/AR048939A1/es unknown
- 2005-05-06 SV SV2005002107A patent/SV2006002107A/es unknown
- 2005-05-06 TW TW094114791A patent/TWI346549B/zh not_active IP Right Cessation
- 2005-05-06 TW TW096139294A patent/TW200815412A/zh unknown
- 2005-05-06 PA PA20058632201A patent/PA8632201A1/es unknown
-
2006
- 2006-10-04 IL IL178433A patent/IL178433A/en active IP Right Grant
- 2006-11-06 CR CR8729A patent/CR8729A/es unknown
- 2006-11-07 MA MA29438A patent/MA28634B1/fr unknown
- 2006-11-08 EC EC2006006975A patent/ECSP066975A/es unknown
-
2007
- 2007-06-07 HK HK07106065.0A patent/HK1100823A1/xx unknown
- 2007-10-24 JP JP2007276853A patent/JP2008050365A/ja not_active Withdrawn
-
2010
- 2010-08-10 CY CY20101100747T patent/CY1110735T1/el unknown
- 2010-08-27 HR HR20100469T patent/HRP20100469T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4173191B2 (ja) | H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 | |
US7456164B2 (en) | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands | |
JP4084410B2 (ja) | ヒスタミンh3受容体リガンドとして有用なテトラヒドロナフチリヂン誘導体 | |
US10005792B2 (en) | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | |
EP2118076B1 (en) | Quinoxaline compounds and use thereof | |
BR112020026748A2 (pt) | Inibidores de quinases dependentes de ciclina | |
AU2006297089A1 (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
JP2017522346A (ja) | ブロモドメインに対して活性な化合物 | |
KR20100015353A (ko) | Jak3 억제제로서의 피롤로피리미딘 유도체 | |
KR20130028732A (ko) | 4―아미노피리미딘 유도체 및 아데노신 a2a 수용체 안타고니스트로서의 이들의 용도 | |
AU2006236387A1 (en) | Subtituted heteroaryl CB1 antagonists | |
CA2952732C (en) | Small molecule agonists of neurotensin receptor 1 | |
JPWO2007114323A1 (ja) | アミノピロリジン化合物 | |
WO2009081259A1 (en) | Phenoxy-pyridyl derivatives | |
WO2007045989A1 (en) | Pyridyl derivatives useful as h3 ligands | |
NZ537629A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders | |
ZA200505957B (en) | Triazole compounds useful in therapy | |
KR20180100705A (ko) | 신규 화합물 및 이의 약학적으로 허용 가능한 염 | |
JP4831966B2 (ja) | 5−ht2a受容体関連疾患の治療のための新規ピペラジニル−ピラジノン誘導体 | |
EP1593679A1 (en) | 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands | |
MXPA06008764A (en) | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation | |
NZ615090A (en) | Guanidine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071024 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071106 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080516 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080805 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080812 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4173191 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110822 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110822 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120822 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120822 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130822 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |